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 I 
ABSTRACT 
Background: Human herpesvirus-8 (HHV-8) is the etiological agent of classic 
Kaposi’s sarcoma (cKS), a lymphoangioproliferative disease found mainly in older 
men of Eastern European and Mediterranean origin. Due to the dual role of B cells 
in HHV-8 infection, virus reservoir as well as agents of humoral immune control, we 
analyzed the subset distribution and the functional state of peripheral blood B cells 
in HHV-8- infected individuals with and without cKS. Furthermore, in order to 
investigate whether the chronic HHV-8 infection in B cells could alter the 
functionality of these cells and particularly may impact on humoral responses to 
antigenic stimulation, we investigated cKS patients’ response to influenza 
vaccination, in terms of clinical efficacy, antibody production and safety. 
 
Methodology: Circulating B cells and their subsets were analyzed by 6-color flow 
cytometry in the following groups: 1- patients HHV-8 positive with classic KS (cKS); 
2- subjects HHV-8 positive and cKS negative (HSP); 3- healthy controls, HHV-8 
negative and cKS negative. Adjuvated trivalent influenza vaccine was administered 
to cKS patients and age- and sex-matched healthy controls. Influenza symptoms 
and side effects were recorded by daily diary cards supplied to the patients. Blood 
analysis and measurement of serum antibodies against vaccine antigens (H1N1, 
H3N2 and B) were performed before, 1 and 3 months post vaccination. 
 
Principal Finding: The number of B cells belonging to the preimmune/natural 
effector compartment, including transitional, pre-naı¨ve, naı¨ve and MZ-like 
subsets, was significantly higher among HHV-8 positive subjects, with or without 
cKS, while was comparable to healthy controls in the antigen experienced T-cell 
dependent compartment. The increased number of preimmune/natural effector B 
cells was associated with increased resistance to spontaneous apoptosis, while did 
not correlate with HHV-8 viral load. The clinical efficacy of vaccination was similar 
in cKS patients and controls. Seroconversion and seroprotection occurred equally 
in both groups. A mild increase in HHV-8 viremia was observed in a proportion of 
cKS patients after vaccination, without concomitant worsening of cKS lesions. The 
safety of vaccination did not differ between cKS patients and controls. The 
frequency of B cell subpopulations was evaluated and did not change after 
vaccination both in cKS patients and in healthy controls. 
 
Conclusions: For the first time to our knowledge, in this study we report that HHV-8 
chronic infection promotes a perturbation of peripheral B cell homeostasis 
characterized by expansion of B cells of the preimmune/natural effector 
compartment, in patients with or without cKS. The alterations observed in cKS 
patients did not lead to an altered response to influenza vaccination that resulted 
safe and immunogenic in cKS patients as well as in age- and sex-matched 
controls. This observation may broaden our understanding of the complex interplay 
between viral and immune factors leading HHV-8-infected individuals to develop 
HHV-8-associated malignancies. Furthermore, our results have clinical importance 
because annual influenza vaccination may be particularly recommended for cKS 
patients considering their advanced age and comorbidity. 
 II 
SOMMARIO 
Introduzione: L’ herpesvirus-8 umano (HHV-8) è l’agente eziologico della variante 
classica del Sarcoma di Kaposi (cKS), una patologia angioproliferativa diffusa 
principalmente tra gli uomini anziani dell’Est Europa o di origine mediterranea. 
Nell’infezione caustata da HHV-8 le cellule B hanno un duplice ruolo: reservoir 
virale e controllo della risposta umorale. Pertanto abbiamo caratterizzato le 
sottopopolazioni e la funzione delle cellule B di sangue periferico in individui infetti 
da HHV-8 con o senza cKS. Per determinare se l’infezione cronica di HHV-8 nelle 
cellule B fosse in grado di alterare la funzionalità di queste cellule e in particolare 
potesse avere conseguenze nella risposta umorale, abbiamo inoltre analizzato la 
risposta alla vaccinazione anti-influenzale in pazienti con cKS, in termini di efficacia 
clinica, risposta anticorpale e sicurezza. 
Metodi: Le cellule B circolanti e le loro sottopopolazioni sono state analizzate con 
metodo citofluorimetrico a 6 colori nei seguenti gruppi: 1- pazienti HHV-8 positivi 
con cKS; 2- soggetti HHV-8 positivi senza cKS; 3- controlli sani HHV-8 negativi 
senza cKS. I pazienti con cKS e controlli sani, simili per età e sesso, hanno 
ricevuto il vaccino anti-influenzale trivalente adiuvato. I sintomi influenzali e gli 
effetti collaterali sono stati registrati in un diario giornaliero fornito ai pazienti. Le 
analisi del sangue e la misurazione degli anticorpi sierici contro gli antigeni del 
vaccino (H1N1, H3N2 e B) sono stati eseguiti prima, uno e tre mesi dopo la 
vaccinazione. 
Risultati: Il numero assoluto delle cellule B appartenente al compartimento 
preimmune/effettore naturale, che include le sottopopolazioni transitional, pre- 
naı¨ve, naı¨ve e MZ-like, è significativamente più alto nei soggetti HHV-8 positivi, 
con o senza cKS, mentre è paragonabile ai soggetti di controllo nel compartimento 
della memoria. Abbiamo osservato che l’aumento del numero delle cellule B del 
compartimento preimmune/effettore naturale è associato ad un’aumentata 
resistenza all’apoptosi spontanea, mentre non è correlato alla carica virale di HHV-
8. L’efficacia clinica della vaccinazione, la sieroconversione e la sieroprotezione 
non differiscono tra pazienti e controlli. E’ stato osservato un lieve aumento della 
viremia di HHV-8 in alcuni pazienti con cKS in seguito alla vaccinazione senza 
tuttavia un concomitante peggioramento delle lesioni. La sicurezza della 
vaccinazione è stata dimostrata sia nei pazienti con cKS sia nei soggetti di 
controllo e infine non sono state osservate variazioni nella frequenza delle 
sottopopolazioni delle cellule B in seguito alla vaccinazione. 
Conclusioni: In questo studio abbiamo dimostrato che l’infezione cronica di HHV-8 
promuove alterazioni nell’omeostasi delle cellule B periferiche, caratterizzate da 
un’espansione delle cellule B del compartimento preimmune/effettore naturale nei 
soggetti HHV-8 positivi con e senza cKS. Tali alterazioni non influiscono sulla 
risposta immunitaria alla vaccinazione, che risulta sicura e immunogenica sia nei 
pazienti con cKS sia nei controlli. I nostri risultati contribuiscono a chiarire il 
complesso rapporto tra fattori virali e risposta immune che conduce allo sviluppo di 
patologie associate ad HHV-8. Inoltre è importante sottolineare la rilevanza clinica 
dei nostri risultati dal momento che la vaccinazione influenzale è raccomandata ai 
pazienti con cKS a causa della loro età in cui la comorbidità è elevata. 
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1. Introduction 
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1.1 KAPOSI'S SARCOMA 
Kaposi's sarcoma, first described by Moritz Kaposi in 1872 as "idiopathic multiple 
pigmented sarcomas of the skin" [1], is an angioproliferative tumour-like lesion 
usually developing in the skin and eventually disseminating to multiple cutaneous 
sites, viscera and lymph nodes [2]. Before 1980 KS was primarily known as a 
disease of older males of Eastern European, Mediterranean, or Jewish 
background. In the early 1980s, KS was found in approximately 40% of American 
men with AIDS [3]. Cross-sectional analysis of the population with AIDS KS 
revealed that the affected population was primarily homosexual men. This 
phenomenon attracted much publicity to AIDS KS, and hence, the other variants of 
KS: classic, endemic, and transplant-associated KS. Although phenotypic features 
are relatively consistent within the 4 subtypes, the clinical course varies [3]. The 
epidemiology of KS in the AIDS population strongly suggested an infectious agent. 
In 1994, Chang et al.,[4] using representational difference analysis, a novel 
technique used to determine subtle differences in DNA sequences between two 
genomes, discovered an uncanny association between a previously unknown virus 
and KS. This includes all subtypes of KS. This virus was named Kaposi’s 
sarcoma–associated herpesvirus (KSHV), and it was subsequently designated the 
eighth human herpesvirus, HHV-8. Since then, HHV8 has also been definitively 
linked with primary effusion lymphoma (PEL) and multicentric Castleman’s disease 
(MCD). Several studies demonstrate that KS is a tumour of multifactorial origin in 
witch viral oncogenesis by HHV8 and cytokine induced growth together with some 
state of immunocompromise represent important conditions for developing this rare 
tumour [5]. 
 
1.1.1 Epidemiology and environmental predispositions 
Cross-sectional epidemiological studies have determined that HHV8 seropositivity 
in various populations is strongly correlated with the population’s risk of KS,[6,7] 
and several longitudinal studies have shown that HHV8 infection precedes the 
onset of KS [8,9]. Ninety to one hundred percent of patients with KS have high 
antibody titers to HHV8, independent of ethnicity and geographic location [10]. The 
seroprevalence varies widely in general populations from different geographic 
areas. The highest seroprevalence of HHV8 is seen in African countries. It is near 
100% in the Ivory Coast; 89% in Gambia; 40% in sub-Saharan Africa; 10% in 
Mediterranean countries; 2% to 4% in Northern Europe, Southeast Asia, and 
Caribbean countries; and from 5% to 25% (most reports are closer to 5%) in the 
heterogeneous United States [11,12]. The incidence of KS is highest in those 
areas with the highest seroprevalence of HHV8 with some exceptions. Although in 
sub-Saharan Africa the 40% seroprevalence correlates well with the high incidence 
of endemic KS, this is not true for the Ivory Coast or Gambia [13]. Although the 
seroprevalence in these countries is extremely high, the incidence of KS is 
minimal, and endemic KS is not known in these regions. Within the United States, 
KS is most commonly seen in 5 homosexual men with AIDS [14]. At one time, 40% 
of this population was reported to have KS. This is a 20-fold increase over non 
homosexual patients with AIDS,implicating a sexual mode of transmission [14]. In 
fact, epidemiologic studies have consistently identified the following risk factors for 
an increased incidence of KS: increased number of sexual partners, HIV-1 
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seropositivity, history of hepatitis A, a history of other sexually transmitted diseases 
such as HSV-2, and receptive anal intercourse. Similarly, the risk of 
seroconversion to HHV8 has been shown to increase with duration of homosexual 
activity, oral genital contact, insertive and receptive anal intercourse, and insertive 
and receptive analingus. [15-17]. Among heterosexuals, a predominant mode of 
HHV8 transmission is less evident. Several studies have shown that women with 
HIV-1 infection have higher seroprevalences of HHV8 than HIV-1–negative women 
and that women engaged in prostitution have higher HHV8 seroprevalences 
[20,21]. However, data from areas where HHV8 is endemic support a nonsexual 
horizontal mode of transmission. 
 
1.1.2 Clinical manifestation 
1.1.2.1 Classic KS 
Classic KS (cKS) occurs as a rare and indolent form in elderly Mediterranean  
men,with particularly high incidence in Italy, Greece, Turkey, and Israel [22, 23]. 
Historically, KS incidence in the Mediterranean is up to 10-fold higher than in the 
rest of Europe and the United States [24,25,26]. Classic KS lesions tend to remain 
confined to the lower extremities and preferentially afflict men rather than women, 
at approximately a 15:1 ratio. Those affected often live with the disease for 10 
years or more and are usually not killed by it [27]. In Italy, seroprevalence and 
incidence increase with age, particularly in males who have reached their 50th 
birthdays [28]. Unlike AIDS-associated KS, HIV-1 coinfection is not typical, but the 
observation that KS develops annually in only 0.03% of HHV8-infected men older 
than 50 years in the Mediterranean strongly suggests the existence of a cofactor(s) 
[29]. Extensive epidemiologic studies in Italy demonstrate a strong influence of 
ethnogeography on HHV8 seropositivity and KS incidence, with a marked gradient 
increasing from the north to the south. The lowest incidences were in northern Italy 
(7.3% HHV8 positive, 0.605 case of KS/100,000 population/year), the highest 
incidences were in the south (24.6% and 1.495/100,000), and a moderate number 
were in central Italy (9.5% and 0.5/100,000) [12]. Two particular southern Italian 
hot spots for KS are on the islands of Sardinia and Sicily: for example, a high rate 
of KS in northern Sardinia is associated with a general seroprevalence of 35%, with 
a range of 15.3 to 46.3% in five areas [28]. However, hot spots also occur in 
lowincidence regions: in the Po Valley in northern (mainland) Italy, the incidence is 
2.5/100,000 men and 0.7/100,000 women, with one rural zone having double the 
male rate and four times the female rate [30]. Elsewhere in Mediterranean Europe, 
a group of blood donors in Spain had a low HHV8 seropositivity similar to that of 
northern Italians [30]. 
The indolent nature of classic KS has made the determination of its prognostic 6 
factors challenging, but the geographic gradient of seropositivity would appear to 
make Italy an ideal setting to identify environmental risk factors. In northern 
Sardinia, the occupation of cereal farming enhances KS risk [31], lending support 
to Ziegler's hypothesis that chronic exposure to the aluminosilicate-rich volcanic 
soils specific to southern Italy may contribute to localized immune suppression in 
the extremities and increased KS risk [32]. However, other studies have failed to 
confirm the connection between type of soil and KS incidence in northeast Sardinia 
[33]. In the Po Valley, residence in areas where malaria was formerly endemic 
corresponded to regions of high HHV8 seroprevalence [34]. Coluzzi et al. make a 
 4 
provocative argument that many of the risk factors identified for classic KS might 
be attributable to high exposure of those populations to blood-sucking arthropods 
[35]. The authors hypothesize that local immunosuppression engendered by 
injection of insect saliva following a bite would prime the tissue microenvironment 
to enhance (i) transmission of HHV8 (from an infected adult's saliva applied as a 
“salve” to a bitten child) or (ii) reactivation of HHV8 in an elderly person, whose 
immune system is already declining. Although this evidence is largely anecdotal, 
the authors propose prospective studies to test their hypotheses and have 
published a recent work provided evidence of an association between the density 
of five mosquito species (Aedes vexans and Aedes caspius, Culex modestus 
Ficalbi, Culiseta annulata, and Coquillettidia richiardii) and KS [36]. Two other 
studies explored the risk associated with age and immune function. Brenner et al. 
[37] retrospectively analyzed all of the classic KS patients (a total of 248) treated in 
two hospitals in northern Israel and Tel Aviv between 1960 and 1995. They 
showed that increasing age at KS diagnosis was prognostic of increasing disease 
progression and that immunosuppression (from steroid treatment or renal failure 
associated with organ transplantation) predicted dissemination. A second study 
found that KS risk was associated with both mild immunosuppression (lower 
lymphocyte and CD4+ cell counts) as well as immune activation (increased serum 
neopterin and β2-microglobulin levels) [38]. Behaviors that influence KS risk have 
been examined by Goedert et al., who demonstrated that increased cigarette 
smoking (measured both in packs per day and in “pack-years”) reduces the risk of 
classic KS fourfold [39]. This study used the powerful comparison of patients with 
both histologically confirmed KS and serologically confirmed HHV8 infection to 
age- and sex-matched controls who were HHV8 positive without KS. Topical 
corticosteroid use, infrequent bathing, and asthma independently increased risk for 
KS in this study [39]. Moreover, recently same Authors have evaluated the 
virologic, haematologic, and immunologic markers of cKS risk and disease burden, 
compared with HHV8-seropositive controls without HIV-infection founding 
thatperipheral blood mononuclear cells (PBMC) HHV8 DNA detection and high HH 
V8 lytic and latent antibody titers were positively associated with cKS risk. 
Moreover, independent of PBMC HHV8 DNA, cKS risk was found to be positively 
associated with reduced hematocrit, hemoglobin, total lymphocytes, including CD4 
positive cells and CD8+ cells, and with increased monocytes [40]. 
Transmission of HHV8 in classic KS probably occurs by both sexual and nonsexual 
routes. Both the close family members and heterosexual partners of KS patients 
show increased HHV8 seroprevalence [41,42], while a group of 51 Catholic nuns in 
Italy had a seroprevalence indistinguishable from that of matched female controls 7 
[43]. Similar to AIDS-associated KS patients, the high frequency of detection of 
HHV8 DNA in tonsillar swabs from HIV-negative KS patients in Italy suggests that 
transmission in saliva is a predominant route [44]. 
 
1.1.2.2 AIDS-Associated KS 
KS is the most common neoplasm in homosexual and bisexual men with AIDS 
[45]; the disease is extremely aggressive in this population and displays a more 
frequent mucosal progression than in the other epidemiologic forms [23]. It 
commonly presents multifocally and frequently on the upper body, head, and neck 
[27], and it evolves quickly, both in local progression of lesions to tumors and in 
visceral dissemination leading to organ dysfunction and high mortality. A direct 
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correlation between HIV-1 infection, AIDS pathogenesis, and KS progression has 
been demonstrated in numerous studies [46-48]. Many conflicting studies have 
demonstrated, however, that the relative contributions of HIV-1 burden and 
immunosuppression to KS development are not always directly proportional [49]. 
Likewise, specific T-cell responses to purified HHV8 virions were reduced in HIV-1 
positive men but were proportional to KS risk in HIV-1-negative men; however, 
both were independent of CD4+ counts [50]. Finally, Veugelers, et al. found that 
age at the time of HHV8 seroconversion may carry more risk than absolute CD4+ 
numbers: older HIV-1-positive men have higher CD4+ numbers at the time of 
seroconversion than do younger men [51]. Furthermore, in the Amsterdam Cohort, 
decreasing CD4+ numbers had no influence on the rate of HHV8 seroconversion 
but, instead, correlated with increased HHV8 replication; this was suggested by an 
increase of antibody titers to a viral structural protein but no change in antibody 
titers to a viral latent protein as CD4+ levels decreased [52]. This study also 
demonstrated that HHV8 seroconversion following HIV-1 seroconversion carries a 
higher risk for KS development than does HHV8 seroconversion prior to HIV-1 
seroconversion [52].  
Sexual transmission of HHV8 in the HIV-infected population is supported by 
numerous data, and sexual behavior is the most significant epidemiologic variable 
in AIDS-associated KS [46]. The risk of developing KS is >10,000 times higher in 
HIV-infected homosexuals than in the general population [45]. Conversely, 
hemophiliacs and injection drug users with AIDS have historically had a markedly 
reduced HHV8 prevalence and KS risk [53]. Furthermore, the disease is 300 times 
more frequent in homosexual and bisexual men than in other immunosuppressed 
individuals [53] and women with AIDS have a fourfold-increased risk of KS if their 
partners are bisexual rather than addicted intravenous drug users [53].  
Recent studies have suggested that orogenital rather than anogenital sex may be 
the most significant behavioral risk factor for HHV8 infection. Although receptive 
anal intercourse was a HHV8 risk factor among homosexual men in the 
Amsterdam Cohort Study [49], participation in orogenital sex was a predictor for 
HHV8 seroconversion [15]. In agreement, many studies have found HHV8 in the 
saliva of seropositive patients [55-57], and HHV8 has been detected in prostate 
tissue and the male urogenital tract [57-60]; detection of HHV8 in the ejaculate has 
been reported but remains controversial [56,59, 61-63]. Taken together, these 
studies affirm a route of sexual transmission for HHV8 that differs significantly from 
that for 8 HIV-1. The increasing and successful use of highly active antiretroviral 
therapy (HAART) has afforded important clinico-epidemiological insights into the 
reversal of AIDS and the consequent fate of HHV8 pathogenesis. Widespread 
HAART has resulted in a yearly declining trend in AIDS-related deaths [64]. There 
is clear evidence that immune restoration due to HAART is one key to improving 
the prognosis of AIDS-KS patients [65]. HAART may reverse KS progression not 
only by inhibiting HIV-1 replication but also by exerting direct effects on KS tumors. 
Considering only current therapies, the fate of AIDS-associated KS in dually 
infected patients will arguably depend on the continued success of HAART 
treatment. 
  
1.1.2.3 Endemic (African) KS 
Prior to the emergence of HIV, African KS was an endemic disease that affected 
mainly two age groups: young men with an average age of 35 years and children 
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with an average age of 3 years [66]. In Cameroon from 1986 to 1993, the latter 
form accounted for about 4% of childhood cancers [67]. The highest prevalence of 
African KS prior to AIDS was found in a broad band crossing equatorial Africa, with 
particularly high rates in northeastern Zaire and western Uganda and Tanzania. 
This geographic pattern conformed to areas of frequent podoconiosis, a lymphatic 
disease of the legs presenting as lymphedema etiologically associated with 
chronic, barefoot exposure to volcanic soils [68]. In podoconiosis, microparticles of 
silica dust in these soils penetrate the skin of the foot during barefoot walking and 
are then taken up by the lymphatics and cause localized inflammation and 
lymphedema. Aluminosilicates are cytotoxic to macrophages in animal models [69] 
and may contribute to localized immune suppression; this had been proposed as 
an environmental contributor to African KS [68]. However, KS on that continent has  
evolved to an epidemic magnitude as the spread of the AIDS pandemic has 
exacerbated the already elevated prevalence of endemic KS. Current 
clinicoepidemiologic studies of African KS as an independent disease entity are 
thus virtually impossible in most contemporary African populations. Clinically, KS in 
Africa is more frequent in children [32, 67, 70] and females than anywhere else 
worldwide and occurs in four forms [27]. One form is similar to classic KS in its 
course but strikes young adults. The other three forms are more aggressive andare 
similar to AIDS-associated KS in their progression: one of these, however, remains 
cutaneous with local tissue invasion, while another occurs most often in young 
children with a mean age of 3 years, is aggressive with visceral progression, but 
often lacks the cutaneous involvement [27]. A comparison of the prevalence of KS 
prior to AIDS with its prevalence during the AIDS pandemic in Africa clearly 
demonstrates the brutal potentiation of KS by HIV-1 coinfection [66]. KS is also the 
leading cancer in Zimbabwe, comprising almost 33% of cancers there [71], 
andaccounts for 15% of male cancers in Zaire [72]. Since the emergence of AIDS, 
the incidence of KS in children has increased 40-fold in Uganda [32], while in 
South African women it has increased at a higher rate than in men: the male-to-
female ratio has decreased from 7:1 in 1988 to 2:1 in 1996 [73]. Overall, while the 
prevalence of KS within the HIV-positive community has skyrocketed, even the 
prevalence of KS in the HIV-negative, “contemporary”-endemic population has 9 
risen. Despite clinical heterogeneity, all forms of KS in Africa are associated with 
HHV8 infection [11,74-77]. HHV8 seropositivity in Africa is quite heterogeneous 
geographically, ranging from 36 to 100% in different countries and populations in 
sub-Saharan Africa [10]. Similar to the situation for U.S. populations, numerous 
studies support the inference that HHV8 was highly prevalent preceding the 
emergence of HIV-1; nonetheless, these studies affirm the critical role of HIV-1 as 
a cofactor in African KS progression. 
The endemic pattern of KS in Africa, especially the high prevalence in childhood, 
reflects the occurrence of primary HHV8 infection before puberty (including during 
infancy). In fact, in many African populations, seroprevalence reaches adult levels 
during adolescence. This early appearance of HHV8 in children in Africa suggests 
that transmission is primarily nonsexual, possibly occurring from mother to fetus 
[78], with clear evidence of intrafamilial and horizontal spread. Indeed, a significant 
risk factor for seroconversion of a child is having a HHV8-infected mother: 42% of 
children born to seropositive mothers were also seropositive when tested between 
0 and 14 years of age, while only 1% of those born to seronegative mothers were 
seropositive [79]. In this study, the potential for vertical transmission of HHV8 was 
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suggested, since one of four infants younger than 18 months born to an infected 
mother was also seropositive. However, many studies argue that a majority of 
seropositive infants acquire maternal immunoglobulins passively from their 
mothers, with vertical transmission of virus remaining possible but rare. For 
example, 83% of Zambian infants were HHV8 seropositive if born to a mother who 
was also seropositive; however, only 3% of the infants had detectable HHV8 DNA 
in their PBMCs [80]. Frequent studies have demonstrated a loss of HHV8 
seropositivity in children after infancy [81-83]. Childhood transmission in Africans 
therefore seems to follow mostly horizontal patterns, with a few vertical instances. 
 
1.1.2.4 Iatrogenic KS 
Iatrogenic KS represents an additional clinicoepidemiologic peculiarity of HHV8 
infection that presents either chronically or with rapid progression [27]. The 
induction of iatrogenic KS by immunosuppressive therapy and its subsequent 
regression on removal of immunosuppression provided some of the earliest clinical 
recognition of the reversibility of KS [27]. Iatrogenic KS shows extreme 
ethnogeographic associations, occurring in only about 0.4% of transplant patients 
in the United States and Western Europe [84,85], but in about 4.0 to 5.3% of renal 
transplant patients in Saudi Arabia [86,87]. Strikingly, KS represents 87.5% of 
posttransplantation neoplasia in Saudi Arabia [88], and a recent study found KS in 
80% of posttransplantation cancers in Turkey. In the latter study, KS developed 
within 1 year in 46% of those cases. The high frequency of iatrogenic KS in Saudi 
Arabia reflects the 7% endemic seroprevalence of HHV8 in healthy Saudi donorsor 
patients with non-KS malignancies [88]. Interestingly, transplant-associated KS  is 
seen predominantly in kidney allograft recipients and not other solid-organ or bone 
marrow transplant recipients [22]; kidney recipients have a greater than two fold- 
higher seroprevalence than those at low risk of KS in France [89]. Although 
Andreoni et al. found that 21.4% of liver recipients, but only 8.6% of kidney 
recipients, seroconverted for HHV8, the risk of KS was higher in the kidney 10 
transplant recipients. In fact, 75% of those who progressed to KS were HHV8 
seropositive prior to transplantation [90]. 
Differences in immunosuppressive therapy might favor HHV8 reactivation in the 
kidney recipients. KS has historically been seen more often in patients whose 
treatment includes cyclosporine [91], a drug that can reactivate HHV8 from 
latencyto lytic replication in tissue culture [61]. Likewise, remission of iatrogenic KS 
on cessation of immunosuppression is the norm. A recent study in Turkey 
demonstrated that 8 of 11 iatrogenic KS patients showed complete regression of 
visceral and cutaneous KS within 6 months of cessation of cyclosporine [92]. A 
recent case study showed regression of cutaneous and mucosal KS after cessation 
of immunosuppressive therapy in a kidney allograft recipient; however, HHV8 DNA 
persisted in the regressed lesions [93]. In recent years, sirolimus has been 
demonstrated as possessing antineoplastic and immunosuppressive properties. 
These effects of sirolimus are due to a common mechanism. Sirolimus inhibits 
mTOR, which links mitogen-induced stimulation of protein synthesis and cell-cycle 
progression [94]. Since 2004, more than 25 recipients with post-transplantation KS 
were treated successfully with sirolimus associated with calcineurin inhibitors 
(Cyclosporine A) (CNI) withdrawal [94,95]. The CNI/sirolimus switch,performed 
immediately after KS diagnosis, is now considered as the first-line treatment of KS 
for transplant recipients [94,95]. Many data support the inference that most 
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iatrogenic KS patients are HHV8 positive prior to transplantation, suggesting that 
reactivation of latent viral infection leads to disease [96]. Although less frequent, 
seroconversion following transplantation suggests that seronegative recipients can 
be infected by HHV8 from the donated organ [96]. Barrozzi et al. studied whether 
HHV8 and the elusive KS progenitor cells could be transmitted from the donor 
through the grafts and showed that the HHV8-infected neoplastic cells in 
posttransplant 
KS harbored either genetic or antigenic markers of their matched donors. These 
data suggest the use of donor-derived HHV8-specific T cells for the control of post-
transplant KS [97]. 
 
1.1.2.5 Mucocutaneous involvement 
Initial clinical presentations at mucocutaneous surfaces begin typically as macular 
and papular lesions that progress to plaque-like or nodular tumours (Fig. 1). 
Lesions vary in size and shape and are generally non-pruritic and painless. The 
colours of the lesions range from pink to deep purple and appear brownish in 
classic KS. While lesions can be found on any body surface they seem to have a 
predilection for the upper body, head, and neck areas in AIDS-KS. Classic and 
iatrogenic KS most often have a preference for the lower extremities. Macular 
lesions are virtually always symptomless and the correct diagnosis is frequently 
missed. Papular and nodular lesions are mostly 1–2 cm in diameter and follow the 
skin tension lines. Lymphatic involvement can give rise to cutaneous and 
subcutaneous complications such as pain, oedema, maceration, and ulceration. KS 
is often accompanied or preceded by local lymphoedema. The coexistence of the 
two events (lymph stasis and vascular neoformation) is probably meaningful in 
these patients [32,98,99]. The observed acral hyperkeratosis may result from 
proliferation of keratinocytes by keratinocyte growth factor (KGF) secreted from 11 
activated fibroblasts [98]. Other variants of KS include: telangiectatic KS 
(translucent nodules with prominent telangiectasia), ecchymotic KS that appears as 
periorbital ecchymoses with a large number of extravasated red blood cells, 
keloidal KS (brown-violaceous nodules with a keloidal component), cavernous KS 
as a rare type of locally aggressive KS that histologically resembles cavernous 
haemangiomas, and lymphangioma-like KS that is a rare variant in which dilated 
vascular spaces produce a bullous-appearing eruption, typically on the lower legs. 
The lesions are easily compressible and appear clinically to be fluid-filled. Visible 
lesions carry a social stigmatisation. Dermal and lymphatic infiltration with KS may 
result in debilitating and cosmetically unacceptable oedema in the periorbital areas, 
genitals, or extremities causing difficulty in walking. Oral lesions are usually 
symptomless, but can occasionally produce obstructive symptoms, pain and 
problems with swallowing [27]. 
 
1.1.2.6 Visceral involvement 
Visceral involvement is common in AIDS-KS but is often symptomless. Post-
mortem studies suggest that more than 25% of patients with AIDS-KS also have 
visceral lesions. They most commonly involve the stomach, bowel, liver, spleen, 
and lungs. Gastric outlet obstruction, enteropathy with small bowel involvement 
and occasionally bleeding of ulcerated KS lesions have been reported. 
Gastrointestinal KS has a typical red, raised appearance and is difficult to diagnose 
by biopsy because of the submucosal location of many lesions. Pulmonary KS is 
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severely debilitating and rapidly fatal if left untreated [47]. Presenting symptoms 
include dyspnoea without fever and occasionally haemoptysis. Chest radiograms 
typically demonstrate diffuse, reticular- nodular infiltrates, mediastinal enlargement, 
and sometimes pleural effusions [100]. Once the diagnosis of KS is clinically 
suspected, it is confirmed by biopsy and histological examination. Although most 
KS lesions are readily recognised, early lesions may be difficult to diagnose and 
other diseases (eg, bacillary angiomatosis or cat-scratch fever) may mimic KS. 
1.1.3 Histopathology 
Spindle cells represent the main cell type of the advanced final nodular stage of KS 
lesions. Despite some clinical and epidemiological differences, the four KS display 
very similar histopathological features, with the proliferation of spindle cells 
(considered as the KS tumor cells) associated with inflammation and neo-
angiogenesis [101]. 
Multicentric neoformation of atypical lymphatics represents the primary process in 
histogenesis of KS. Important cell interactions are presumed to occur between 
fibroblasts, monocytes and endothelial cells. The remarkable symmetry of lesions 
and the concept of multicentric origin of KS fit well with this hypothesis. Patch-
stage KS, the earliest pattern, typically arises in the reticular dermis as a clinically 
macular lesion. A proliferation of small, irregular and jagged endothelium lined 
spaces surrounding normal dermal vessels and adnexal structures accompanied 
by a variable, inflammatory lymphocytic infiltrate (with or without plasma cells) is 
characteristic [102]. Plaque-stage KS, the histological correlate of small palpable 
lesions, represents the expansion of a spindle-cell vascular process throughout the 
entire dermis (Fig. 2), at times extending to the subcutaneous fat. Spindle cells are 
dispersed throughout dermal collagen bundles forming irregular, cleft-like, 
angulated vascular channels containing varying numbers of erythrocytes. 
Haemosiderin deposits and eosinophilic hyaline globules are typically present. A 
perivascular inflammatory infiltrate is usually found [103]. Histiocytes with the 
phenotype of either factor XIIIa or S-100 dermal dendritic cells as well as T-cells 
and B-cells including plasma cells are also present [103,104]. Nodular-stage KS 
lesions are composed of sheets and fascicles of spindle cells with mild to moderate 
cytological atypia, single cell necrosis, and trapped erythrocytes within an 
extensive network of slit-like vascular spaces. Vessels lack a prominent investment 
of pericytes and have a fragmented basal lamina and frequent discontinuities in the 
endothelial lining. Erythrophagocytosis and necrosis of individual endothelial cells 
may also occur [105]. 
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1.1.4 Staging 
Staging this multicentric disorder has been a challenge. The value of each scheme 
is limited. Moreover, KS may sometimes have an acute onset and rapidly 
progressive course, or undergo sudden worsening that complicates a previously 
chronic and generally undemanding evolution. Taylor’s first classification [106] 
referred to the classical and endemic forms considered clinical, behaviour and 
localization criteria common to all variants. The recognition of AIDS-related KS 
made it necessary to broaden the staging criteria: Kriegel suggested a 4-stage 
subdivision that included the parameters of visceral sites and systemic involvement 
[107], whereas the classifications of Mitsuyasu [108] and Chachowa and Krown 
[109,110] introduced the concept of prognosis but only referred to the AIDS-related 
variant. There are other staging ideas, including thoughtful ones by Cottoni and 
Montesu [111] and Schwartz et al [112]. However, the staging systems elaborated 
after the rise of AIDS-related KS are not suitable for cKS, as the former worsens 
rapidly with early spreading to visceral organs in the context of severe 
immunodeficiency mostly lacking in cKS.  Moreover, the heterogeneity of clinical 
presentation and the variability of evolution of cKS make difficult the staging of the 
disease. Brambilla et al. [113] have identified additional clinical parameters that 
have been included in a new staging system which is applicable to the classic 
forms of KS and may represent a useful tool for therapeutic choices. Table 1 
summarises staging system proposed by Authors which includes four clinical 
stages: 
ñ Stage I (maculo-nodular): small isolated angiomatous maculae and/or 
nodules, prevalently localised in lower limbs; 
ñ Stage II (infiltrative): prevalent violet-grey plaque lesions involving wide 
areas of lower limbs, sometimes associated with a few nodules; 
ñ Stage III (florid): exuberant angiomatous plaques and nodules, often 
ulcerated, involving one or more limbs; 
ñ Stage IV (disseminated): presence of a significant number of angiomatous 
A B 
Figure 1: Hystology of cKS lasion. A) Hematoxilin and eosin stained section of 
dermal KS showing cord of spindle cells and slit-like vascular spaces. B) High 
magnification view of KS spincle cells showing their drammaticaly elongated 
morphology [101]. 
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plaques and nodules involving other skin districts in addition to the limbs. 
Moreover, in Table 1, the "Evolution" column refers to the speed of disease 
progression (A: slow and B: rapid), with rapid being defined as an increase in the 
total number of nodules/plaques or in the total area of plaques in the three months 
following an examination. Furthermore, complications which can be present in all 
the stages are considered: objective ones, such as ulcerations, bleeding, 
lymphedema, lymphorrhea, and subjective ones, such as pain, functional grip 
and/or ambulatory impotence. The presence of lesions in visceral sites (the gastro-
enteric tract, including the oral cavity, the lymph nodes and the lungs) is also taken 
into account, although internal localization is a rare event, prevalently confined to 
the oral cavity and gastric area in stages III and IV. Considering the speed of 
evolution and the presence of complications may be helpful for prognostic and 
therapeutic evaluations in the context of a modified disease staging. 
 
Table 1. cKS staging and therapeutic choices 
Stage  
Skin 
lesions 
Localizati
on  
Behavio
ur 
Evoluti
on  
Complicatio
ns*  
Therapy 
I 
Maculo-
nodular 
(±v)  
Nodules 
and/or 
macules  
Lower 
limbs 
Non 
aggressiv
e 
Slow (A) 
Rapid 
(B)  
•Lymphede
ma 
•Lymphorrea 
Elastic 
stocking; 
intralesional 
chemothera
py only for 
nodule 
II 
Infiltrative 
(±v)  
Plaques  Lower 
limbs  
Locally 
aggressiv
e 
Slow (A) 
Rapid 
(B) 
•Hemorrhag
e •Pain 
Elastic 
stocking; 
intralesional 
chemothera
py only for 
nodule 
III 
Florid (±v)   
Angiomat
ous 
nodules 
and 
plaques  
Limbs, 
lower 
prevalent  
Locally 
aggressiv
e 
Slow (A) 
Rapid 
(B) 
•Functional 
impairment  
Elastic 
stocking; 
intralesional 
and 
systemic  
chemothera
py- 
IV 
Dissemina
ted (±v) 
Angiomat
ous 
nodules 
and 
plaque 
Limbs, 
trunk, 
head  
Dissemin
ated 
aggressiv
e 
Rapid 
(B) 
•Ulceration Systemic 
and 
intralesional 
chemothera
py, elastic 
stocking  
v: visceral involvement (pharyngo-oral cavity, gastroenteric tract, lymph nodes, 
bone marrow, lungs). 
Rapid: increase in total number of nodules/plaques or in total area of plaques in 
the three months following an examination. 
*All of them prevalent in stage III and IV, lymphedema and lymphorrea often 
observed in stage II, lymphedema and hemorrhage sometimes present in stage 
I. 
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Moreover, Authors have found that most of the patients with maculo-nodular (stage 
I) or infiltrative (stage II) disease have a slow evolution without complications, thus 
allowing to avoid systemic chemotherapy administration. These patients, who can 
be adequately monitored by means of examinations every 2-3 months, could be 
treated with intralesional chemotherapy and/or elastic stockings.  However, 
systemic chemotherapy is used in the case of stage II patients with slowly evolving 
complicated disease or rapidly evolving disease with or without complications, and 
in all variants of stage III and IV disease. Brambilla and co-authors employ classic 
chemotherapy and not interferon immunotherapy because the latter causes 
clinically significant systemic side-effects in elderly patients. Proposed therapeutic 
choices based on this classification of cKS patients, are summarised in Table 1. 
1.1.5 Pathogenesis of KS 
Although necessary for KS development, HHV8 infection is not sufficient to 
engender KS. From 2%–7% of the U.S. population has serologic evidence of 
infection [6,74], yet most of these individuals have no discernable KS risk, which 
clearly indicates that cofactors are required for tumorigenesis. In AIDS-related KS, 
the cofactor is obviously HIV infection. HIV’s cofactor role in KS is strongly 
supported by (a) the dramatic reduction in KS incidence that has accompanied 
reduction of HIV viremia via antiretroviral therapy [114,115] and (b) the remission of 
clinical KS in patients treated with HAART alone [116,117]. Exactly how HIV 
infection promotes KS development is still a matter of controversy. There is 
laboratory evidence that in certain settings HIV infection can augment HHV8 
replication in both cell-autonomous and paracrine fashions [118-120], but the in 
vivo relevance of these observations is unclear. (For instance, because dually 
infected cells are rare in vivo [60], cell-autonomous interactions between these 
viruses are unlikely to be critical). Ensoli and colleagues have argued for a role for 
secreted HIV tat protein as a growth factor for KS spindle cells, again on the basis 
of experiments in cultured cells (reviewed in Reference 121). However, the 
interpretation of these data is complicated by the fact that cultured spindle cells 
tend to lose the HHV8 genome (see below) and so cannot be relied upon to model 
faithfully all aspects of KS biology. Certainly, in the context of the whole organism, 
HIV infection is associated with cytokine upregulation, and such an environment 
should be conducive to sustaining spindle-cell survival and growth. Moreover, the T 
cell depletion and immunodeficiency induced by unchecked HIV replication is 
certain to be a factor in the progression of KS as it manifestly is in KS linked to 
iatrogenic immunosuppression. The controversy about HIV’s role in KS 
development is unlikely to be resolved in the near future. However, it is worth 
pointing out that none of the models just summarized are mutually exclusive. 
 
Instead, the identity of the cofactor(s) in classical KS remains unknown. 
Accumulating evidences suggests that cKS is a multistep process involving both 
viral and cellular factors, which include infection of spindle cells by HHV8 and 
production of several inflammatory cytokines, chemokines and angiogenic factors. 
From an initial reactive and inflammatory process, some selective pressure and 
or/genetic alterations may give rise to nodular tumoral KS lesions, consisting of a 
neoplastic oligoclonal proliferation of spindle cells. There are three extraordinary 
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and overlapping developments with regards to the pathogenesis of KS: the HHV8 
infection, the deregulation of immune system and the role played by the 
inflammatory microenvironment. 
1.1.5.1 HHV8 
Concordant with its homology to lymphotropic viruses, the discovery of HHV8-DNA 
in KS specimens was soon followed by detection of the virus in cultured cells from 
patients with primary effusion lymphoma (PEL), a rare AIDS-associated B-cell non-
Hodgkin's lymphoma. The ability of PEL cells to support continuous HHV8 infection 
and conditional, productive replication was crucial for the subsequent cloning and 
nucleotide sequencing of the entire viral genome and for direct visualization of 
mature herpesvirus-like HHV8 virions by electron microscopy [122]. The complete 
nucleotide sequence of HHV8 confirmed its classification as a rhadinovirus, or 
gamma-2-herpesvirus, joining the gamma-1-herpesvirus EBV as the only human 
gammaherpesviruses. Similar to the HVS and EBV genomes, the HHV8 genome is 
maintained during latency in PEL cell lines as a circular, multicopy episome and 
contains multiple GC-rich, 801-bp terminal repeats flanking approximately 145 kb 
of “unique” sequence  [123] (Fig. 3).  
 
During productive replication, viral progeny DNA is ultimately synthesized as linear, 
single-unit genomes destined for incorporation into independent virions. 
Cryoelectron microscopy and digital reconstruction demonstrate that the capsid is 
icosahedral with a diameter of approximately 1,140 to 1,300 Å [124].  The 
characteristic herpesvirus tegument and envelope presumably are added to the 
Figure 2: HHV8 genome map. Upon infection, HHV8 genome is delivered 
to the nucleus where it circularizes. During the latent programme, a small 
number of proteins (indicated in green) are expressed to maintain the viral 
episome, to avoid host antiviral immune responses and to provide a growth 
advantage to infected cells. Latently infected cells can be induced to enter 
the lytic cycle under specific physiological conditions. Lytic replication leads 
to extensive viral gene expression. Lytic gene expression is tightly 
regulated (viral genes transcribed early upon reactivation are indicated in 
yellow, those transcribed during intermediate kinetics in orange, and those 
transcribed during late kinetics in red). HHV8-encoded microRNAs are 
indicated by grey arrowheads [149]. 
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capsids during egress. HHV8 contains at least 87 open reading frames (ORFs) 
[123] (Fig. 3). Comparison of its genome with that of HVS (the prototype 
gammaherpesvirus) reveals a remarkably similar genetic organization. The two 
family members share 68 conserved genes that are arranged colinearly, with short, 
interspersed regions of genes unique to each virus. Each conserved gene has 
been given the prefix “ORF” and numbered consecutively from left to right along 
the genome, while the unique genes have been designated K1 to K15 [125]. The 
87 HHV8 genes iclude both homologues of cellular proteins (named like the cellular 
protein with a v- before the name to indicate the viral origin) and unique HHV8 
proteins (like Latency-associated nuclear antigen LANA and the Kaposins). 
As noted above, HHV8 DNA is present in all KS tumors, irrespective of clinical 
type. Viral infection selectively targets spindle cells [60,126,127], with little or no 
infection of other cell types (though monocytes in the lesions may be infected) 
[128]. Like all herpesviruses, HHV8 can adopt either of two replicative programs, 
which are known as latency and lytic replication. In latency, viral gene expression is 
heavily restricted, with only a handful of viral genes being expressed; viral DNA is 
retained as a circular episome in the nucleus, and no progeny virions are 
produced. In contrast, lytic replication involves the temporally regulated expression 
of virtually the entire viral genome, with viral DNA replication and production of 
infectious progeny, in the course of which the host cell dies. Lytic replication can be 
induced from the latent state by the induction of theexpression of a single viral 
gene, which encodes a transcription factor known as RTA (replication and 
transcription activator) [129,130]. In vitro, this can be achieved by the treatment of 
latently infected cells with phorbol esters or sodium butyrate or by transfection with 
constitutively active RTA alleles. The stimuli to HHV8 lytic reactivation in vivo are 
unknown, but there is evidence that some cytokines can trigger such reactivation in 
culture [131,132]. The latency program is assigned the primary role in 
oncogenesis, by both promoting cell growth and impairing apoptosis. The lytic 
cycle, by contrast, has traditionally been thought not to contribute directly to 
oncogenesis because cells that enter this program invariably die. Of course, it has 
long been acknowledged that lytic replication plays an important early role in viral 
oncogenesis by allowing the virus to spread throughout the host. This exposes 
many tissues to the virus and allows the establishment of many latent foci, which 
can then begin their long mutational march to cancer. Most KS spindle cells are 
latently infected with only a small subpopulation of spindle cells (1%–3%) display 
lytic replicative markers [60, 126]. This finding accords with conventional notions of 
the role of latency in tumors. Examination of early (patch) lesions of KS shows that 
only 10%–30% of spindle-like cells express latent genes [126], whereas in later 
lesions virtually all such cells are latently infected [60,126]. This clearly implies that 
latently infected cells have a growth or survival advantage in vivo.  
However, the discovery that the HHV8 latency program does not appear to be 
strongly immortalizing has raised questions about whether latency really suffices to 
drive KS pathogenesis unassisted. In fact, independent evidence from clinical 
studies suggests that lytic replication also plays a pivotal role in KS development. 
In patients with advanced AIDS, treatment with ganciclovir (GCV), a drug that 
blocks lytic but not latent HHV8 infection, results in a prompt and dramatic decline 
in the incidence of new KS tumors [133]. How might lytic replication contribute to 
KS tumor development? There are three nonexclusive possibilities: (i) spindle cells 
are not immortalized in vivo, then in order for a tumor mass to expand, HHV8-
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positive cells that die must be replaced by new latently infected cells. The most 
obvious source of such cells would be from de novo infection of endothelia with 
viruses produced by lytic replication; (ii) If, as noted above, HHV8 latency is 
unstable, then as spindle cells proliferate, they would be expected to rapidly lose 
the viral genome. For KS to progress, cells that lose the HHV8 genome must be 
replaced by cells newly recruited to latency by de novo infection with viruses 
produced by lytic replication. (iii) The third manner by which lytic HHV8 replication 
may contribute to KS pathogenesis harkens back to the view that KS is a 
composite of three processes: proliferation, inflammation, and angiogensis. 
Because lytically infected cells die, they cannot contribute significantly to the 
proliferative component of the disease. However, if lytically infected cells produce 
paracrine signaling molecules, they could promote both the inflammatory and 
angiogenic components of the lesion. In fact, examination of the HHV8 genome 
[134] reveals numerous viral genes whose products are secreted signaling 
molecules—many of which are homologs of cellular cytokines or chemokines. The 
majority of these are lytic-cycle genes, including the three viral CC chemokines and 
v-IL6. 
1.1.5.2 Deregulation of immune system 
To efficiently establish a persistent infection, HHV8 dedicates a large amount of its 
coding potential to produce proteins that antagonize the immune system of its host. 
These viral immunomodulators interfere with both the innate and adaptive immune 
responses and most of them are homologous to cellular proteins, suggesting that 
they have been pirated from the host during viral evolution. The HHV8 genome 
contains 87 genes, of which at least 22 are potentially immunomodulatory (Table 2) 
on both adaptive and innate immune responses, including T- and B-cell functions, 
complement activation, the innate antiviral interferon response and natural killer 
cell activity. Reports of CD4+ T-cell responses to HHV8 antigens are very limited, 
but such antigens have been described [135]. By contrast, many reports have 
described responses to HHV8 by CD8+ cytotoxic T lymphocytes (CTL), and 
multiple epitopes have been identified in latent and lytic proteins [136-137]. 
Nevertheless, CTL responses to HHV8 in KS patients are considerably less 
frequent than in asymptomatic HHV8-seropositive subjects, regardless of CD4+ T-
cell count [135]. Based on current evidence, the explanation of this observation 
could be related to a loss or sequestration in KS lesions of HHV8-specific CTLs 
from the periphery and/or to a suppression of their anti-HHV8 function. Down-
regulation of the levels of MHC-I molecules on the surface of antigen presenting 
cells (APC) could be an effective method of suppressing CTL responses to virus-
infected cells. HHV8 infects myeloid dendritic cells, macrophages and B cells 
through a receptor called DC-SIGN [138]. This infection reduces MHC-I expression 
in B cells [139] in addition to antigen processing and presentation in dendritic cells 
and macrophages. Several HHV8 proteins have the capacity to effect MHC-I down-
regulation. They might function in concert, at different times during the viral 
lifecycle or in different host cells. The MIR1 and MIR2 protein trigger endocytosis 
and proteasomal degradation of MHC-I by ubiquitinating its cytoplasmic tail [14]. 
MIR1 and MIR2 have different requirements for the proximity to the 
transmembrane domain of their target residues for ubiquitination, which could, 
therefore, determine the portfolio of cellular proteins down-regulated by each of 
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these viral proteins: MIR2 preferentially ubiquitinates residues closer to the 
membrane than MIR1 [140].  
 
 
 
 
KSHV protein KSHV gene
 
Anti-interferon
ORF45 ORF45 None Inhibition of IRF-7
RTA ORF50 None Inhibition of IRF-7
K2 IL-6 Cell growth
K6, K4, K4.1
ORF74 IL-8 receptor Cell growth
K12 None
K13 (ORF71) FLIP
16
K7
KCP ORF4 DAF
MIR1, MIR2 K3 (ORF12), K5 None
K1 K1 ITAM
K15 K15 None
vOX2 K14 CD200
SOX ORF37 None
Table 2. KSHV immunomodulatory proteins
Cellular 
homologue
Immunomodulatory 
function
1) Modulation of cytokines and cytokine receptors
vIRF-1, vIRF-2, 
vIRF-3, vIRF-4
K9, K11.1/K11, 
K10.6/K10.5, 
K10.1/K10
Interferon-
regulatory factors
vIL-6
vCCL-1, vCCL-
2, vCCL-3
Macrophage 
inflammatory 
proteins
Chemokines
vGPCR
Kaposin B Increased stability of 
mRNAs containing 
AU-rich elements
2) Modulation of apoptosis
vFLIP Inhibition of apoptosis
vBcl-2 Bcl-2 Inhibition of apoptosis
vIAP IAP (survivin) Inhibition of apoptosis
Regulation of complement
 
Complement 
regulation
Deregulation of cell–cell contact
 
MHC class I 
downregulation (E3 
ligase)
Downmodulation of B 
cell-receptor 
expression
B cell-receptor 
signalling
Other immunomodulatory activities
 
Myeloid-cell regulator
Host shutoff
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Classically, the corollary to MHC down-regulation on the cell's surface is increased 
recognition of that cell by natural killer (NK) cells. Likewise, NK cells express a 
battery of activating receptors, including NKG2D, 2B4 and NKp80. NKG2D 
recognizes MHC-I-related chains (MIC) A and B, whereas NKp80 recognizes the 
activation-induced C-type lectin (AICL). In HHV8 infected cells, MIR2 reduced 
surface expression of ICAM-1 and B7-2 [141] and MICA, MICB and epitope-tagged 
AICL [142], protecting against NK-mediated lysis. However, the contribution of NK 
cells to HHV8 infection biology and the relative importance of modulating their 
activity remain to be determined unequivocally. Given that HHV8 can infect APCs, 
including B cells and dendritic cells, its down-regulation of the MHC-II antigen 
presentation pathway might be anticipated. However, we are not aware of any 
evidence to support this possibility. 
As weel as T cells, the virus seems to influence several aspects of B-cell biology, 
with modulation of the immune response (Fig. 4). HHV8 also encodes miRNAs: 
twelve have been identified within the latency-associated region [143,144]. One of 
them, miR-K12–11, is an orthologue of miR-155. This miRNA is a contributor to B-
cell differentiation and phenotype implicated in germinal centre development and, 
by regulating the activity of the enzyme activation-induced-deaminase (AID), 
antibody diversity. HHV8-miRNAs seem to regulate either the same cellular genes 
or genes involved in similar cellular processes [145]. Thus, there is every 
expectation that HHV8 miRNAs will be found to modulate immune function, and 
perhaps other aspects of pathogenesis, including oncogenesis [38]. Moreover, The 
HHV8 type I membrane glycoprotein K1 e the protein K15 might also influence B-
cell biology. K1 retains BCR complexes in the endoplasmic reticulum, hence 
reducing the presence of BCR on the cell surface [146], instead K15 interacts with 
components of the clathrin-mediated endocytic pathway and might accelerate BCR 
internalisation (Fig. 4)  [147].  
 
 
 
 
 
Figure 3: Summary of the mechanisms of HHV8 modulation of B cell function. The 
B cell is one likely reservoir of latent KSHV infection. However the three 
immunoregulatory proteins depicted are most abundantly expressed during lytic 
replication. K1 reduces the presence of BCR on the cell surface. Phosphorylation 
of the ITAM motif from K1 results in recruitment of various signalling proteins 
containing SH2-domains that participate in the production of cytokines, inhibition of 
apoptosis and cell transformation. K15 can also repress signalling from the BCR. 
MIR2 protein down-regulates BST-2 (also called tetherin), which is implicated in 
normal and malignant B-cell differentiation [123]. 
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Little is known about the phagocytosis of opsonised HHV8 virions, although the 
HHV8 v-OX2 protein can inhibit neutrophil function [123]. HHV8 could also interact 
with the Complement system. In particular HHV8 ORF4 encodes a protein, known 
as HHV8 complement regulatory protein (KCP) [148], possessing complement 
regulatory activity. The protein is a lytic cycle protein that is incorporated on the 
surface of the virion [148]. Here it can participate in cell infection via the known 
HHV8 cell-attachment factor heparan sulphate, in addition to inhibiting 
complement-mediated immune responses. Molecular studies of recombinant KCP 
have revealed that it accelerates the decay of the classical pathway C3 convertase, 
and acts as a cofactor for factor I-mediated inactivation of C3b and C4b 
(components of the C3 and C5 convertases) facilitating binding of the virus to the 
cell and evasion of complement. 
Arguably IFN-α and IFN-β are the most important and certainly the most 
understood of the IFNs associated with innate immunity to be activated in response 
to virus infection. Remarkably, HHV8 encodes four proteins (called v-IRFs) with 
limited homology to the cellular IRFs. In addition to the effect on MHC-I (see 
earlier), v-IRFs negatively regulate cellular IFN signalling. v-IRF1 inhibits the 
transcriptional programs induced by exogenous IFNs specifically by blocking 
transcriptional activation by the cellular proteins IRF1 and IRF3. The other lytic viral 
IRF, v-IRF3, is most closely related to the cellular IRF4 and also blocks IFN 
signaling by functioning as a dominant negative inhibitor of IRF3 and IRF7. Other 
HHV8 proteins also participate in regulating the IFN-mediated antiviral response. 
The K8 -encoded K-bZIP protein, the virion-associated ORF45 protein and RTA. 
The plethora of strategies adopted by HHV8 to inhibit the antiviral IFN response 
indicates that such modulation is important to HHV8 survival. However, complete 
abrogation of the IFN response is rarely achieved [149].  
Chemokines activate leukocytes and regulate their trafficking. HHV8 encodes three 
chemokine homologues expressed during lytic replication and called viral CC-
chemokine ligand 1 (v-CCL1), v-CCL2 and v-CCL3. Together they have numerous 
immune regulatory activities, but overall they probably polarize the adaptive 
immune response toward a Th2-like, or humoral, response [123]. Aside from their 
roles in immune modulation, these viral chemokines are angiogenic and anti-
apoptotic for endothelial cells [150]; these activities might contribute to HHV8 
pathogenesis. Moreover, HHV8 produce v-IL6 that retains sequence and functional 
homology to cellular IL-6. It stimulates multiple cellular pathways to induce cell 
proliferation and extrahepatic acute-phase responses through engagement of the 
gp130 coreceptor independently of the IL-6 (gp80) receptor [149]. v-IL-6, but not 
human IL-6, protects PELs and heterologous cells from the antiviral, cytostatic 
effects of IFN-α, which down-regulates the surface expression of gp80 but not 
gp130. In fact, v-IL6 transcription is induced indirectly by IFN-α and v-IL6 induces 
human IL6 secretion, supports the growth of IL6 dependent cell lines. Cells stably 
expressing v-IL6 secrete increased VEGF and induce hematopoiesis, 
tumorigenesis, and angiogenesis when injected into nude mice [149]. 
1.1.5.3 Kaposi’s sarcoma: a model of chronic inflammation                                                       
Many aspects of KS suggest that chronic inflammation plays a role in its 
pathogenesis. At first glance, it seems counter-productive for a virus to encode 
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both proteins that evade the immune system and proteins that activate the immune 
system. However, in the context of chronic inflammation it makes perfect sense. It 
appears that inflammation is primarily mediated by hyperactivation of the humoral 
arm of the immune system (Th2-mediated responses) and is often accompanied by 
a decrease in the cellular immunity (Th1-mediated responses), which is the more 
effective antiviral response. We have already discussed many of the mechanisms 
used by HHV8 to downregulate the Th1-mediated responses such as suppression 
of IFNs and MHC-1 downregulation, so we will now turn to the mechanisms that 
the virus uses to activate the inflammatory responses, which lead to continued 
inflammation and KS tumor progression. 
1.1.5.3.1 Pro-inflammatory cytokines  
Several studies indicated that a network of soluble inflammatory cytokines 
promotes KS lesion development and progression by acting both in an autocrine 
and paracrine fashion. In particular, all patients with KS or at risk for KS show signs 
of immune activation such as increased levels in blood of intercellular adhesion 
molecule 1, neopterin, soluble CD8, and inflammatory cytokines, including IL1, IL6, 
TNF, IFN-γ (reviewed in Reference 132). In addition, high levels of inflammatory 
cytokines are detected in early KS lesions, which are infiltrated by numerous CD8+ 
T cells and monocytes that precede KS spindle cells appearance. Altogether, these 
data suggest that inflammatory cytokines may behave as KS “initiating factors” 
since they trigger the production of angiogenic factors which, in turn, promote KS 
development and progression. Clinical evidence confirms that immune activation 
rather than immunodeficiency may play a role in lesion development. In particular, 
both patients with classic KS and those with African KS show evidence of CD8+ T-
cell activation with production of Th-1-type cytokines [151]. In addition, AIDS-KS 
not only can arise in the absence of immune deficiency [152], but it also develops 
in individuals showing signs of immune activation and Th-1-type cytokine 
production [153]. Furthermore, treatment of AIDS patients with recombinant 
inflammatory cytokines has resulted in KS onset or progression [154]. Finally, 
immune activation is likely to occur also in post-transplant KS in which, in spite of 
immune suppressive therapy, allogeneic stimulation may induce local foci of 
activated immune cells. Thus, immune activation and inflammatory cytokine 
production initiate KS, whereas immune defects and HHV8 escape mechanisms 
may be key for KS progression. Paradoxically, the immune response against HHV8 
may even exacerbate KS progression via production of inflammatory cytokines 
[155,156]. In fact, the increased inflammatory cytokines in individuals with (or at 
risk for) KS induce both endothelial cells and leukocytes to express adhesion 
molecules which mediate the adhesion of HIV-infected, HHV8-infected, or 
uninfected leukocytes to the endothelium and their migration into tissues [155]. The 
recruitment of leukocytes in the lesion is enhanced by several chemokines (e.g., 
MIP1α and -β, RANTES, monocyte chemotactic protein-1, IL-8, Mig, and IFN-γ-
inducible protein 1) that are expressed by KS spindle cells, activated leukocytes, or 
endothelial cells [157].  It is noteworthy that inflammatory cytokines reactivate 
latent HHV8, increasing the virus load and inducing virus spread to all blood cells 
[118,156].  
Moreover,  HHV8 encodes for a protein that stimulates the proinflammatory 
immune response: vGPCR. The constitutive activity of the v-GPCR induces myriad 
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signaling molecules. These include NF-κB, which has become increasingly linked 
to chronic inflammation and cancer progression. The activation of these various 
pathways by v-GPCR in monocytes and T cells leads to the production of 
proinflammatory cytokines including IL-1β, TNFα, IL-6, IL-2, IL-4 [158] v-GPCR 
induced activation of NF-κB in endothelial cells results in expression of RANTES, 
IL8 and GM-CSF as well as the adhesion molecules VCAM-1, ICAM-1 and E-
selectin [159]. Due to the lytic expression of vGPCR, any effects this signaling has 
on tumor formation or progression probably occurs via a paracrine mechanism. 
HHV8 also induces NF-κB via the expression of v-FLIP. Because v-FLIP is latent 
and, therefore, widely expressed in KS and PEL tissues, the activation of NF-κB is 
constitutive, not transient. This constant signaling from the tumor tissue could be a 
major stimulus for both proliferation and chronic infiltration by leukocytes. Very 
important is the role played by IL6, a cytockine that has long been associated with 
KS and MCD tumor development. It has been shown to enhance proliferation of KS 
cells in culture and was found in high levels in blood from MCD patients, which 
correlated with disease progression [149]. The viral homologue v-IL6 induces all of 
the same signals as its cellular counterpart, but because it does not require IL-Rα 
for signaling, more cells are susceptible to activation [149]. 
1.1.5.3.2 Angiogenesis 
The formation of new blood vessels to increase blood supply to a site of injury is 
another normal inflammatory response of the immune system that, when aberrantly 
stimulated, enhances tumor pathogenesis. Among the angiogenic factors 
expressed by KS spindle cells in vitro and in vivo, basic fibroblast growth factor 
(bFGF) is a key mediator of KS lesion formation since it promotes both KS spindle 
cells and endothelial cells locomotion and proliferation in an autocrine and 
paracrine manner, respectively [131,132]. Injection of bFGF in mice results in the 
formation of KS-like lesions, while bFGF antagonists that include specific antisense 
oligodeoxynucleotides or neutralizing antibodies block the development of 
angioproliferative lesions induced by primary KSC upon injection in nude mice 
[131.132]. Another angiogenic molecule expressed in vitro and in vivo by KS 
spindle cells is the vascular endothelial cell growth factor type A (VEGF-A) 
[160,161], a homodimer belonging to the cysteine knot family of growth factors. In 
KS lesions, VEGF-A is responsible for edema formation and synergizes with bFGF 
in inducing endothelial cell growth and angiogenesis [160,161]. Moreover, VEGF-
C, another member of the VEGF family, stimulates the growth of some KS spindle 
cells isolates which, similarly to lymphatic endothelial cells, express the receptor for 
this angiogenic factor. HHV8 encodes several other proteins that induce VEGF. For 
example, v-IL6 and all three HHV8-encoded chemokines (vCCLs) have been 
shown to induce angiogenesis in experimental models, and the mechanism for this 
activity is likely the induction of VEGF [162]. Similarly, it has also been shown that 
in HHV8-infected endothelial cells, vGPCR upregulates both VEGF and its receptor 
VEGF-R2.44 It has been postulated that this may create a paracrine feedback loop 
for continued cellular proliferation and angiogenesis [163]. 
                 
In conclusion, most of the proinflammatory cytokines and angiogenic factors 
produced or induced by HHV8 likely evolved to create a highly proliferative 
environment for viral genome maintenance and reactivation from latency. Both lytic 
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and latent genes are responsible suggesting that both autocrine and paracrine 
mechanisms are involved. In addition to the virally induced factors, the persistent 
infection induces a constant infiltration of leukocytes, which also secrete a large 
variety of cytokines, chemokines, MMPs and IFNs that favor the growth of the 
infected cells and adds to the progression of KS. Theese evidence suggest that, 
from a pathogenetic point of view, it is useful to think of KS as being composed of 
three parallel processes: a proliferative component (involving chiefly spindle cells), 
an inflammatory component, and an angiogenic component. Although it is likely 
that these processes are interdependent and perhaps mutually reinforcing, thinking 
of them as individual entities allows the virologist to entertain different models for 
how viral gene expression may influence each component and thus affect the 
lesion as a whole. 
1.1.6 Spindle cells and their role in Kaposi’s sarcoma 
The term spindle cell was first used by the German pathologist Kobner in 1883 and 
then by Philippson in 1902. Spindle cells are defined as the characteristic cells, 
exhibiting a typical spindle-shaped morphology, which are mostly present in the 
advanced stage of the KS lesions. 
 
Indeed, these peculiar cells, which are considered to be the KS tumor cells, 
represent the most prominent histo-pathological feature of the final nodular stage 
of KS. These cells clearly represent the main proliferative element in KS, but 
analysis of their clonality has shown that many KS lesions are oligo- or 
polyclonal—again reinforcing how different KS is from traditional cancer [164,165]. 
Although this conclusion has been disputed by some research [166], even these 
dissenting studies have shown evidence of non-clonality in numerous tumors, and 
the recent work by Duprez et al. [167] strongly suggests the oligoglonal origin of KS 
lesion. Although spindle cells are considered the driving force behind KS 
histogenesis, they are by no means the sole cell type in the tumor. As described, 
all KS lesions also contain significant numbers of inflammatory cells (B and T cells, 
plasma cells, and monocytes) and a profusion of aberrant, slit-like neovascular 
spaces [126]. Moreover, one criterion for malignant transformation in cell culture is 
the reduced dependence upon exogenous growth factors. However, cultured KS 
spindle cells, unlike classical tumor cells, remain highly dependent upon 
exogenous growth signals when cultured in vitro. Ensoli and colleagues were the 
first to grow KS spindle cells in culture and found them to be strongly dependent 
upon a cytokine-rich medium derived from supernatants of activated T cell cultures 
[75,132]. To date, no less-complex medium that regularly allows spindle-cell 
outgrowth has been found, and certainly such lines do not grow in low-serum 
medium, nor do they display genetic instability, another hallmark of traditional 
cancers. KS spindle cells are generally diploid, and no characteristic chromosomal 
rearrangements are shared by multiple tumors. Classical KS lesions do not display 
microsatellite instability, although some advanced AIDS-KS lesions do [168]. 
Cultured KS spindle cells also lack other markers of transformation. They do not 
form foci, nor grow in soft agar, nor form tumors in nude mice [101]. However, an 
interesting phenotype is observed when the cells are injected subcutaneously in 
nude mice. Although they do not generate a tumor, they do survive for a brief 
interval, during which slit-like new vessels of murine origin appear in the 
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surrounding tissue. When the human implant involutes, these vessels likewise 
disappear [167]. This suggests a KS model in which spindle cells require growth 
factors from their microenvironment (perhaps from infiltrating inflammatory cells) for 
their survival and proliferation, but also produce angiogenic and proinflammatory 
substances to recruit the other components of the lesion. In this view, none of the 
partners in this process are fully autonomous; each depends upon the other (Fig. 
5).  
All in all, most clinical and experimental observations about KS suggest that the 
differences between this disorder and classical cancers are at least as numerous 
as their similarities. It should then come as no surprise that the viral contributions to 
KS pathogenesis may be more variegated than those of other tumor viruses to 
more traditional cancers. 
1.1.6.1 Cell origin 
The question of the spindle cell origin has been a matter of animated debate and 
several cell types have been considered during the last decades. Researchers 
have long thought that spindle cells are of endothelial lineage, and indeed they 
bear many endothelial markers, including CD31, CD34, CD36, factor XIII, En-4, 
and PAL-E [103,131,132,170]. However, most spindle cells lack staining for factor 
VIII, a classical marker of differentiated vascular endothelium, and Weibel-Palade 
bodies are absent ultrastructurally [101]. Confusion has been compounded by the 
finding that KS spindle cells display significant heterogeneity in marker expression. 
For example, a small number of cells in some biopsies do stain for factor VIII, 
whereas other cells stain for smooth muscle α-actin [103,131,170], leading some 
researchers to speculate that spindle cells may arise from bipotential mesenchymal 
precursors of vascular cells. Another view is that the cells arise from lymphatic 
endothelium, a notion that has been encouraged further by the observation that 
clinical KS virtually never arises in tissues that lack lymphatics (e.g., the central 
nervous system) [3], and that molecular markers of lymphatic endothelium (VEGF-
C, VEGF-R3, podoplanin, and LYVE-1) are also expressed regularly by spindle 
cells in vivo [171,172]. Two recent studies have examined the effects of KS-
associated herpesvirus (HHV8) infection on the gene-expression programs of 
cultured vascular and lymphatic endothelium using DNA microarrays to profile 
host-gene transcription [173,174]. Although these studies are conducted in vitro 
perforce, they may help explain the heterogeneity observed in marker expression 
in biopsies, and they certainly complicate attempts to discern the lineage of 
infected cells on the basis of patterns of marker expression alone. They reveal that 
viral infection reprograms endothelial marker expression, which causes vascular 
endothelium to express certain lymphatic markers, whereas lymphatic endothelium 
shifts to a more vascular-like marker profile. Theese findings indicates that KS 
spindle cells do not faithfully represent either cell lineage, which could be a 
consequence of HHV8 infection [173]. Based on these evidences, the more likely 
scenario is that HHV8 infected endothelial precursor cells circulate in blood driving 
these precursors towards lymphatic phenotype and that after infections, they may 
go to permissive sites to proliferate as KS lesion or grow following transmission of 
HHV8 to dermal microvascular endothelial cells [175]. Moreover, others two 
considerations suggest that KS lesions may originate from the seeding of 
previously infected endothelial precursors. The first consideration derives from the 
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observation that KS lesions often progress during or following states of systemic 
inflammation, and that KS tumors sometimes arise precisely at sites of previous 
local inflammation, such as surgical wounds (a property known as the Koebner 
phenomenon) [176], thus suggesting that an inflammatory environment can elicit 
spindle cell proliferation from circulating HHV8-infected precursors. The second 
and more stringent consideration derives from the demonstration that recipients of 
kidney allografts HHV8-negative prior to transplantation may develop KS lesions 
containing HHV8-infected neoplastic cells of donor origin. This observation clearly 
indicates that infected progenitor cells from HHV8-infected donors without KS can 
be seeded and undergo neoplastic transformation and progression in the recipient 
immunosuppressed hosts [97]. Although it is possible that donor-derived KS 
precursors might be mature endothelial cells of the kidney, it appears far more 
likely that they may originate from circulating endothelial progenitors entrapped 
within the graft. 
1.1.6.2 In vitro culture of spindle cells  
Several laboratories have succeeded in establishing cell lines derived from KS 
cells using conditioned media and/or diverse inflammatory cytokines, in vitro. 
These cells, originating from classic/epidemic KS lymph node, from skin biopsies or 
from pleural effusion of KS patients, exhibit a spindle-shaped morphology. 
However, they are quite heterogeneous, as some cell lines express mainly 
endothelial cell markers (with or without blood vessel or lymphatic markers, 
depending on the cell-line), while others present a smooth muscle phenotype or 
even mesenchymal markers [170]. Theese cell lines have been extensively 
characterized and used in several animal models (such as nude mice), in order to 
gain new insights into KS pathogenesis. However, one of the most puzzling 
features of spindle cell biology has been the fact that every spindle cell line that 
has been derived has been shown to lack the HHV8 genome [177,178], despite the 
fact that in advanced primary KS tumors nearly all spindle cells are latently 
infected. The reasons for this have been uncertain, but it is noteworthy that 
numerous cell lines have been derived from HHV8-associated primary effusion 
lymphomas (PELs) in which HHV8 genomic persistence is readily demonstrable. 
This indicates that there are circumstances under which stable latency is achieved 
in vivo and that standard culture conditions are not incompatible with this state, at 
least in B cells. Moreover, this marked propensity to segregate latent viral genomes 
is shered also by proliferating cells infected with HHV8 in vitro. In fact, they display 
only a variable but small subpopulation being capable of stable episome 
maintenance [179]. To explain this paradox many studies suggest that stable 
maintenance of viral genome is not due to the enhanced production of viral or host 
trans-acting factors, but is associated with cis-acting, epigenetic changes in the 
viral chromosome [179]. These results indicate that acquisition of stable HHV8 
latency is a multistep process that proceeds with varying degrees of efficiency in 
different cell types. 
1.1.7 B cells and HHV8 infection 
Soon after the discovery of HHV8 in the spindle cells of KS tumors, HHV8 was 
found associated with two B-cell lymphoproliferative disorders: multicentric 
Castleman disease (MCD) and primary effusion lymphoma (PEL). There are further 
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reports of HHV8-positive lymphomas with clinical, histological and 
immunophenotypic features distinct from the above HHV8-associated 
lymphoproliferative disorders in patients both with and without immunodeficiency 
[5]. Together, these studies show that HHV8 is associated with a wide spectrum of 
lymphoproliferative disorders with varied clinicopathological features. Moreover, 
several studies demonstrated that in KS patients, HHV8 establishes persistent 
infection in peripheral blood B lymphocytes witch represent the major virus 
reservoir. The virus is able to interact with B lymphocyte in several ways: (1) 
generating a immune evasion strategy for elicit B cell response; (2) skipping the B 
cell developmental pathways; (3) inducing B cell lymphoproliferation by the switch 
of both latent and lytic genes and by the affection of specific pathways of B cell 
proliferation, including cell cycle check points and the Notch and Wnt signalling 
pathways. The first point was already discussed (see Figure 4), in this section we 
will examine the others points to clearly understand the mechanisms of interaction 
between HHV8 and B cells in KS and in the lymphoproliferative diseases 
associated with HHV8 infection. 
1.1.7.1 HHV8 interferes with the B cell developmental pathways 
In the HHV8 positive plasmablastic variant of MCD of plasma cells type and in the 
frank plasmablastic lymphoma, the HHV8-positive plasmablasts phenotypically 
resemble mature B-cells. For example, they express abundant cytoplasmic 
immunoglobulin and many express CD27 [180,181], a surface marker for memory 
B-cells. However, HHV8-positive plasmablasts in MCD consistently show a lack of 
somatic mutations in their rearranged immunoglobulin heavy and light chain genes 
[181], indicating that they originate from pre-germinal centre B-cells. This, together 
with the predilection of HHV8-positive plasmablasts to localise in the mantle zone 
of B cell follicles, suggests that HHV8 may preferentially target IgM  expressing 
naïve B-cells in patients with MCD and drive the infected cells to differentiate into 
plasmablasts without going through the germinal centre reaction (GCR), a critical 
process for normal B-cell maturation [180,182]. Therefore, HHV8 may infect IgM-
positive naïve B cells and drive these cells to differentiate into plasmablasts and 
form lymphoproliferative lesions without undergoing the GCR. Among all the HHV8 
genes, the first responsible for these effects could be v-IL6 that is a potent factor of 
B cell survival. Indeed, it has been suggested that HHV8 encoded v-IL6 may play a 
direct role in driving HHV8 infected naïve B cells to differentiate to plasmablasts 
and contribute to the development of lymphoproliferative lesions, without the need 
for the transition of the lymphoma precursor cell through the GCR [180,182]. Also 
the latency protein LANA could participate to this process, as suggests by the 
recent study by Fakhari et al. [183]. The Authors, using transgenic mice that 
expressed LANA protein in mature B cells, found that LANA activated mature B 
cells in the absence of antigen stimulation, which predisposed the animals to 
lymphoma development. In particular, all of the transgenic mice developed splenic 
follicular hyperplasia due to an expansion of IgM+IgD+ B cells [183].  
Moreover, HHV8 encodes for two proteins, K1 and K15, able to subvert BCR 
signalling during lytic replication and perhaps also during latency in B cell. The viral 
protein K1 protein interacts with the heavy chains of the BCR, retaining this 
complex in the endoplasmatic reticulum and preventing it from reaching the cell 
surface [146]. The viral protein K15, instead, can inhibit the BCR signal 
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transduction by reducing tyrosine phosphorylation and intracellular calcium influx 
[141].  This strategy may then usurp control of infected-cell signalling altering the 
normal developmental pathway and extending the life of the infected cell to 
maximize progeny virion production. 
Another possible mechanism of interaction between HHV8 and the developmental 
pathway of B cells may come from the study of viral micro-RNAs. Computer 
analysis of potential mRNA targets for these viral micro-RNAs, has identified a 
number of interesting candidate cellular genes, involved in a range of cellular 
activities, including apoptosis and signalling, one of which is, for example, BCL-6, 
targeted by HHV8 micro-RNA-K4 [143]. The theoretical possibility is raised that 
targeting BCL-6 by viral micro-RNA-K4 may lead to its down-regulation, followed by 
the up-regulation of BLIMP-1 and by the shift of a B cell towards a plasma cells 
stage of differentiation. This and other studies on the possible role of HHV8 micro-
RNAs in B cell proliferation and transformation may contribute to shed lights into 
the various and reciprocal interactions between host and herpesviral genes, 
helping to dissect the fine tuning of B cell fate. 
1.1.7.2 HHV8 induced B cell proliferation 
HHV8 genome contains viral genes which are homologous to cellular genes 
involved in the control of proliferation and apoptosis. Such viral genes that are 
pathogenetically relevant for HHV8 driven lymphoproliferation are expressed during 
either the latent or the lytic phase of the viral cycle and control cellular functions, 
directly [184]. Several viral protein are able to to induce B cell proliferation in 
different ways.  
Normally, during viral infection, host cells induce the antiviral factor IFN-a to up-
regulate p21, initiate cell cycle arrest and inhibit viral replication. Moreover, IFN-a 
down-regulates the human IL6 receptor gp80. However, a viral transcription 
programme exists in which IFN-α also activates the HHV8 v-IL6 promoter to induce 
the secretion of v-IL6, which, in turn, by-passes the gp80 negative regulatory check 
point, by binding directly to its other receptor, the gp130 receptor, which is not 
down-regulated by IFN-a and thus is free to induce B cell survival and proliferation 
[185,186]. Additionally, HHV8 encode proteins that inactivate p53 or Rb [182]: 
LANA and v-cyclin, both expressed in HHV8 positive lymphoproliferative lesions in 
vivo, inactivate p53 and Rb, respectively. LANA inhibits p53-mediated apoptosis by 
inactivating Rb, v-cyclin induce the release of E2F, which is normally inhibited by 
Rb, and initiate the transcription of genes involved in DNA synthesis (such as DNA 
polymerase, thymidine kinase, etc.) [182]. 
Moreover, HHV8 could affect specific pathways of B cell proliferation, including the 
Notch and Wnt signalling pathways. The Notch receptor and the Notch ligands are 
transmembrane proteins that influence cell fate decisions, proliferation and 
differentiation. HHV8 has developed a mechanism to alter this pathway through the 
protein RTA that binds the nuclear mediator of Notch and activates either cellular 
(CD21, CD23) or viral (v-IL-6) genes [187]. The Wnt signalling pathway regulates 
development and proliferation. In particular, the Wnt signalling regulates the 
effector molecule Beta-catenin through a complex containing glycogen synthase 
kinase 3beta (GSK-3beta), adenomatosis polyposis coli, and axin. This complex 
efficiently phosphorylates Beta-catenin, promoting its degradation by the 
proteosome. In PEL, HHV8 LANA binds and traps GSK-3beta in the nucleus, 
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resulting in inefficient phosphorylation and degradation of Beta-catenin, which, 
thus, may accumulate and is free to enter the nucleus and to activate genes 
involved in cell proliferation [187]. 
1.1.7.3 HHV8 infects B cells in KS patients 
Several reports have demonstrated that B lymphocytes are preferentially infected 
by HHV8 [188-190]. However, there are contrasting results on the percentage KS 
patients that harbour HHV8-infected B cells, ranging from low percentage [188] to 
81% [189]. Although the percentage of infected B cells in these patients is a very 
small fraction of B lymphocytes, B cells are now defined as one of the principal 
circulating virus reservoir. This hypothesis is supported by the finding that B cells 
isolated from patients with KS or at risk of KS sustain the reactivation of HHV8 
infection after exposition to inflammatory cytokines [156]. Therefore, several 
Authors suggest that circulating B cells may recruit the virus into tissues and may 
undergo lytic infection and transmit the virus to neighbour cells. 
Peripheral B cells are HHV8-infected in KS patients, and HHV8 might also be 
involved in the transformation of B cells. Therefore, several studies have 
investigated a possible association between cKS and lymphorpoliferative disorder 
(LD). The first report of an association between KS and a LD dates back 
approximately 90 years [191]; later, a large number of reports of followed but the 
results collected in various studies of large series of homogeneous patient 
populations with nonepidemic KS have not always been concordant [192-195]. A 
recent work by Hiatt et al. [196] demonstrates an increased incidence of multiple 
myeloma and non-Hodgkin’s lymphoma in a cKS population in USA. These non-
Hodgkin lymphomas include angioimmunoblastic lymphadenopathy, B-cell 
immunoblastic lymphoma, autoimmune hemolytic anemia, and hairy cell leukemia. 
These contrasting results of association could be explained by considering the 
temporal relationship of occurrence of KS and LD. It has been postulated that the 
development of secondary malignancies, including LD, after the diagnosis of KS in 
HIV negative and positive patients is not increased [192,193]. Conversely, the risk 
of developing KS after LD is high due to immunosuppression secondary to 
chemotherapeutics, infectious agents, and radiotherapy, and even in those patients 
with benign lesions treated with corticosteroids and/or azathioprine [196]. 
Therefore, further studies are needed to definitively asses the relation between KS 
and LD, and to verify the hypothesis that infected B cells could be driven towards a 
transformed phenotype. 
 
Thus, B cells in KS patients are viral reservoir able to sustain the lytic reactivation 
and dissemination of the virus. In addiction, B cells are one of the target of viral 
proteins able to promote a modulation of B cell functions. It is conceivable that 
evolutionary pressure has selected B lymphocytes as the site of HHV8 latency also 
for making these cells relative incapable to stimulate a strong immune response 
against the virus. 
 27 
1.2 B cell development: from precursor to antybody producing 
plasma cell 
The discovery that lymphocyte subpopulations participate in distinct components of 
the immune response focused attention onto the origins and function of 
lymphocytes more than 40 years ago. Studies in the 1960s and 1970s 
demonstrated that B and T lymphocytes were responsible primarily for the basic 
functions of antibody production and cell-mediated immune responses, 
respectively. The decades that followed have witnessed a continuum of unfolding 
complexities in B-cell development, subsets, and function that could not have been 
predicted. The phenotypic and functional diversity of B lymphocytes, their 
regulatory roles independent of antibody production, and the molecular events that 
make this lineage unique are also poorly defined [197]. Recently many studies 
demonstrated that B cells outside the marrow are morphologically homogenous, 
but their cell surface phenotypes, anatomic localization, and functional properties 
reveal still-unfolding complexities [197]. B lymphocytes are generated via several 
sequential steps of differentiation (Fig. 8), from precursor to antibody producing 
cells. 
 
 
 
 
Figure 4: Scheme of B cell development. The central and peripheral B cell 
developments are outlined. Blood represents circulating B cell populations. 
Relevant surface markers for each differentiational step are listed. fo B cell, 
follicular B cell (naïve B cell); GC, germinal center; mem B, memory B cells; MZ B 
cell, marginal zone B cell; Pbl, plasmablast; Trans or Transit, transitional B cell 
[261]. 
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1.2.1 Central B cell development 
The early development of human pro and pre B cells from pluripotent stem cells is 
antigen independent and takes place in the bone marrow. 
Pro B cells (CD19-CD10+/-CD20-CD22+CD24- vpreB-Ig -/+) are characterized by 
the expression of the first B cell specific surface marker CD22. Late pro and early 
pre B cells commence assembling the immunoglobulin surface receptor (BCR) and 
its signaling components. The completed rearrangement of the heavy chain and 
pairing with the surrogate light chain on the surface as the Pre B cell receptor 
(preBCR) marks the pre B cell stage [199].  
Pre B cells (CD19+ CD10+CD20-CD24highvpreB+Ig + intracellular +) expressing 
correctly assembled preBCR on the surface are positively selected for proliferation 
and further differentiation. Deletion of B cell specific transcription factors BSAP, 
E2A, EBF, responsible for the transcription of the BCR, the recombinase-activating 
genes RAG1 and -2, responsible for the rearrangement of the -heavy (and later 
light) chains, pre BCR components ( -chain, Ig , Ig , 5, vpreB) and downstream 
signaling components, like Syk, Slp65, and btk, cause severe blocks at the pro-/pre 
B cell transition [200]. Defects of some of these signaling molecules have been 
identified in immunodeficient humans [201]. 
 
After the successful assembly of the preBCR and several rounds of expansion, 
kappa or lambda light chains replace the surrogate light chain. The pairing of the  
heavy chain and a light chain finally leads to the surface expression of IgM, the 
hallmark of immature B cells. Immature B cells 
(CD19+CD10+CD20+CD24++IgM+) are most likely positively selected for the 
successful recombination of heavy and light chain. Simultaneously, the expression 
of the BCR on the surface allows for the first time antigen-specific negative 
selection. At this stage the central development of B cells is accomplished and so-
called transitional B cells leave the bone marrow for full maturation in secondary 
lymphoid organs, especially the spleen. Neither pro-, pre-B cells are found in the 
circulation of healthy humans [202]. 
1.2.2 Peripheral B cell development 
B cells generated in the bone marrow migrate to the periphery at the transitional B-
cell stage, when they are still short-lived and functionally immature [203,204]. 
Transitional B cells are transported by the bloodstream to the spleen. Here they 
develop into long-lived mature B cells. Similar to the early stages in the bone 
marrow [205], this phase of development in the spleen also requires the presence 
of a functional B-cell receptor (BCR) and of a supporting microenvironment. 
In mice, peripheral B cells pass through several consecutive developmental stages 
termed transitional B cell T1-2 or 3 [206,207]). Transitional type 1 (T1) B cells 
(IgMhighIgD-CD21-CD23-) resemble the immature B cells of the bone marrow. In 
the splenic environment T1 B cells differentiate into T2 B cells 
(IgMhighIgD+CD21intCD23+). Beside BCR-derived signals, BAFF (synonym: Blys) 
and its receptor BAFF-R (synonym: BR3) [208] have been shown to be key 
regulators for the survival at this stage. BAFF-R belongs to the TNF receptor family 
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and is almost exclusively expressed on B cells. While early precursors have no 
detectable expression, transitional T2 B cells are the first to express BAFF-R on 
the surface [209,210]. The development of human transitional B cell seems to 
resemble the described murine differentiation at least in part [211]. 
It is unclear how T1, T2 and T3 subsets relate to stages of human B cell 
maturation. However, it is clear in both mice and humans, B cell development 
during the transition from immature to mature naïve B cells is a multistep process, 
and at each step B cells are influenced by selection pressure to ensure tolerance 
before full maturation [211]. Intermediate cell subsets during human peripheral B 
cell development have not been fully characterized. 
 
Recently, circulating human transitional B cells were identified in the peripheral 
blood oh adult by studing CD38, CD10, and CD24 expression, previously identified 
as immature B-cell markers in bone marrow [212]. Phenotype analysis revealed 
that approximately 14% of cord blood B cells and 2-4% of peripheral B cells 
expressed these immature B-cell markers and a phenotype similar to that 
described for murine transitional type I (T1) B cells: these cells are CD19+, 
CD24high,CD38high, CD21low, CD23neg/low, IgMhigh, IgDlint, and CD62Llow. The 
increased expression of CD20 and reduced expression of CD40 and CD22 was 
found on these human B cells have also been reported on murine T1 B cells 
[206,213]. The lack or diminished expression of activation markers, such as CD69, 
CD11b, CD80, CD86, and CD95, compared with memory or recently activated B 
cells indicates that these cells are unlikely to have responded to antigen recently 
[212]. The absence of both CD27 expression and Ig somatic hypermutation 
demonstrates that these cells are not memory B cells [214]. There were differences 
between murine T1 B cells and their putative human counterparts. The most 
notable difference was the expression of CD5 on the latter [211,214]. CD5 
expression is associated with a subset of murine B cells known as B1a cells that 
are predominately found in the peritoneum and express low affinity BCRs with 
autoreactive specificity [215]. The immature markers on T1 B cells, particularly the 
increased expression of CD24, low expression of CD11b, and their poor survival, 
distinguishes them from murine B1a B cells [216]. Moreover, Ig gene usage and 
substantial nontemplated nucleotide addition are not characteristic of either murine 
peritoneal B1a cells or human fetal B-cell repertoires [217]. Notably, the initial B 
cells emerging from bone marrow following human stem cell transplantation are 
CD5+ [218]. Therefore, CD5-expressing immature B cells represent T1 B cells 
rather than B1a cells, and could be an useful marker for identification of human 
transitional B cells [211,212].  
Since T1 B cells express low levels of the adhesion molecules CD62L and CD44 
compared with mature B cells their capacity to migrate is limited [219]. 
Nevertheless, the expression profile of circulating T1 B cells and the relative 
stability of this population following immunization distinguish these cells from pre-
GC and plasma cell precursors [212]. Moreover, human T1 B cells died rapidly in 
culture without any stimulation, a feature common to mouse splenic T1 B cells 
[207,218]. Furthermore, CD24highCD38high B cells displayed other immature 
characteristics, including: unmutated Ig V genes, elevated levels of surface IgM, 
lacked expression of Bcl-2, greatly reduced capacity to proliferate, secrete Ig, and 
migrate in vitro compared with mature B cell populations [220].Thus, 
CD24highCD38high B cells appear to represent a unique population of human B cells, 
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with morphological, phenotypic, and functional characteristics that distinguish them 
from mature B cells and would be consistent with their designation as transitional B 
cells.  
 
Importantly, intermediates in human B cell development can be found in the 
peripheral blood [212], raising questions about the site(s) of maturation of these 
cells in humans.  Recently, Lee et al. [220] identified a distinct pre-naïve B cell 
population circulating in human peripheral blood that exhibits an intermediate 
phenotype between transitional and naïve B cells. Like human transitional B cells, 
these cells express CD5 but have intermediate densities of CD38, CD10, CD9, and 
the ABCB1 transporter compared with transitional and naïve B cells. These pre-
naïve B cells account for a majority of circulating human CD5 B cells. Importantly, 
CD5 pre-naïve B cells could be induced to differentiate into cells with a naïve 
phenotype in vitro. CD5 pre-naïve B cells show only partial responses to BCR 
stimulation and CD40 ligation and undergo more spontaneous apoptosis and cell 
death than do naïve B cells, whereas BAFF/BLyS (B cell-activating factor 
belonging to the TNF family) did not enhance their survival compared with naïve B 
cells. In contrast, CD5 pre-naïve B cells carry out certain functions comparable to 
naïve B cells, including the capacity to differentiate into plasma cells and the ability 
to function as APCs [220]. 
 
After passing the transitional stage, the human mature B cell compartment consists 
of naïve B cells and marginal zone B cells [201]. It is not known whether a human 
equivalent of the murine B1 B cell compartment exists. The murine marginal zone 
of the spleen contains a sessile IgMhighCD21highCD23lowCD9+ B cell population (MZ 
B cells) which is a crucial player of the early antibody response, especially to 
blood-borne, T independent but also dependent antigens [221]. 
In humans, MZ B cells have been identified as CD27+IgMhighIgD+ B cells and 
represent about 15-25% of the circulating B cell pool [222]. BCR specificities for 
polysaccharides like pneumococcal polysaccharides (PnPS) are enriched among 
the MZ B cells and a decrease of circulating MZ B cells is associated with a poor 
PnPS vaccination response [221]. 
Naïve B cells express CD23, CD21 and are IgM+, and IgD+, but do not express 
CD27. They represent the main B cell population in the blood and secondary 
lymphoid tissues of mice and men. Most of their BCRs recognize proteins and 
therefore naïve B cells are typically recruited in T cell dependent responses. This 
allows for the participation in germinal center reaction and differentiation into long-
lived memory B cells or plasma cells [200]. 
1.2.3 Antigen Driven B Cell Differentiation of Mature B Cell Compartments 
Depending on BCR signal strength, activation of costimulatory receptors, and other 
factors, antigen activation of mature B cell leads either to death or further 
differentiation into the memory or plasma cell pool [200]. 
When successfully activated, B cells enter the FDC network inside the B cell 
follicles and give rise to germinal centers around day 3-5 of T dependent antibody 
responses [223]. Germinal centers are a highly specialized niche, crucial for class 
switch recombination, affinity maturation, selection, and expansion of antigen-
specific B cell clones [224]. Additional T cell derived signals, foremost by CD40L, 
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allow these cells to survive and acquire characteristics of memory B cells. Other 
stimuli including IL10, IL21 [225] induce a part of germinal center cells to enter an 
alternative pathway of differentiation generating plasma cells [226]. During the 
germinal center phase B cells go through several stages (BM1-5) [227], of which 
only the pre (naïve, BM1-2) and post germinal center (memory, BM5) stages can 
be found in the circulation.  
1.2.4 B Cell Memory and Plasma cells 
It is well established that following an immune response two types of differentiated 
B cells persist in the memory pool: plasma cells, which confer immediate protection 
by the secretion of specific antibodies; and memory B cells, which confer rapid and 
enhanced response to secondary challenge [228]. Longevity remains the key 
aspect of immunological memory and applies to both plasma cells and memory B 
cells. In humans all memory B cells recirculate through the blood, but their main 
reservoir is represented by lymphoid tissues, such as the bone marrow and the 
spleen [229]. Their survival requirements remain to be defined. Mouse studies 
indicate that BlyS is required for the maintenance of naïve B cells and APRIL for 
the maintenance of plasma cells, while both ligands appear to be dispensable for 
the survival of memory B cells [230,231]. However, there is evidence that under 
steady-state conditions human memory B cells are slowly dividing [232] suggesting 
that the memory B cell pool may be maintained through homeostatic proliferation 
as it is the case for memory T cells. This view is supported by the observation that 
memory B cells are highly responsive to polyclonal stimuli [232]. At present a B 
‘memory stem cell’ has not been identified and remains a matter of speculation. 
 
While the identification of murine B cell memory suffered from the lack of specific 
surface markers, human memory B cells can be identified by the expression of 
CD27 [229]. About 16-55% (5-95% confidence interval) of circulating B cells are 
CD27+ B cells of which about 50% express IgM and IgD while the rest has 
undergone class switch recombination with only a very low percentage of post 
germinal center IgM-only (IgM+IgD-CD27+) B cells in the peripheral blood [248]. 
Several lines of evidence point out that the IgM+IgD+CD27+ B cells represent 
marginal zone B cells (see above) [228,229]. Therefore only IgD- are true post 
germinal center memory B cells, and could be further divided in class-switched 
IgM- IgD- CD27+ B cells and IgM memory B cells IgM+ IgD- CD27+, a small 
popolation representig 1% of total B cells [230]. 
 
Plasma cells emerge from extrafollicular as well as germinal center responses. 
During primary antigen encounter plasmablasts form antibody forming foci (AFC) in 
the medullary cords of lymph nodes and in the red pulp of the spleen [232]. These 
plasma cells can switch to IgG1, carry only few SHM and are short lived [296]. In 
contrast, postgerminal center responses can create a long lasting humoral 
immunity. Plasma cells are not circulating and only few plasmablasts are 
detectable in the peripheral blood. The number depends on recent activation and 
increases around day 6 after vaccination to return soon back to below 2% [295]. 
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1.3 Influenza vaccine responses in older adults 
1.3.1 Influenza—a significant cause of morbidity in older adults 
Vaccination is of crucial importance in preventing infection and protecting the 
vulnerable elderly population from disease. Because the efficacy of a vaccine 
depends on the quality of the immune response, immunocompromised persons, 
such as very young infants and elderly people, are likely to be insufficiently 
protected. Thus, over the past decade, a large number of studies have shown that 
a variety of vaccines are less efficient in elderly persons. Annual vaccination 
against influenza, for example, is recommended in most developed countries for 
persons with underlying chronic diseases and for everybody aged >60 or >65 
years, depending on individual national recommendations. 
The full impact of influenza is increasingly recognized as an illness that goes well 
beyond pneumonia and influenza statistics. Peak months of mortality due to 
respiratory illness, ischemic heart disease, cerebrovascular events and diabetes in 
adults 70 years and older coincide with annual influenza epidemics, suggesting 
that influenza illness is the major cause of excess mortality in this population during 
the winter months [233]. Hospitalization and death rates from influenza are rising in 
spite of widespread influenza vaccination programs implemented in the 1990s. 
Influenza on average resulted in 36,000 deaths annually in the U.S. from 1990 to 
1999 [234], almost double that of the period from 1976 to 1990. A similar rise in 
hospitalization rates for acute respiratory illnesses and cardiovascular diseases 
during the influenza season was also observed over these two time periods [235], 
[236]. 
 
1.3.2 Link to immune senescence 
A decline in immune function is a hallmark of aging and affects the ability to resist 
influenza infection and respond to vaccination. It is recognized that multiple 
components of immune function, particularly cell-mediated immunity, are affected 
during the aging process. As a consequence, there has been a paradigm shift in 
understanding the limitations of antibody titers as a sole measure of influenza 
vaccine efficacy in older people [237], [238], [239], [240], [241] and [242]. In this 
population, adequate antibody titers may not provide sterilizing immunity, where 
antibody fails to bind the influenza virus to prevent infection of the cell [243],[244]. 
Further, statistically significant increases in antibody titers that correlate with 
protection in response to vaccination, may not translate to clinically important 
improvements in influenza outcomes in older adults [245]. Thus, the goal of 
vaccination may be clinical protection against illness when infection occurs and is 
mediated by both humoral and cellular immune mechanisms. The challenge to new 
vaccine development is that antibody titers as a sole predictor of vaccine efficacy 
may fail to detect important changes in cellular immunity that enhance vaccine-
mediated protection in older people. 
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1.3.3 Antibody and cell-mediated immune responses to influenza 
vaccine 
Influenza virus stimulates an antiviral response in both B and T lymphocytes 
resulting in humoral and cell-mediated immunity, respectively. Virus-activated T-
cells, through cytokine mediators, stimulate B-cells to differentiate and produce 
antibodies specific for a particular vaccine strain. These specific antibodies bind to 
the surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), to 
neutralize the virus particle. Influenza vaccines must be updated annually to 
include the predicted circulating strains of influenza A/H3N2 and A/H1N1 and 
influenza B. Antibody responses to influenza vaccination have largely been 
evaluated by the hemagglutination inhibition (HI) assay. While the HI test is 
convenient and considered a gold standard, virus neutralization assays are gaining 
more acceptance as they are considered more functional. 
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Figure 5: Scheme of the response to vaccination; APC, antigen presenting cell; Th, 
helper T-cell; type 1, Th1; type 2, Th2; CTL, cytotoxic T lymphocyte; B, B cell; IL, 
interleukin; IFN, interferon; TNF, tumor necrosis factor; Grz B, granzyme B; Ab, 
antibody; HI, hemaglutination inhibition; SN, serum neutralization; ADCC, antibody 
dependent cell-mediated cytotoxicity, CML, complement-mediated lysis. 
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Human herpesvirus-8 (HHV-8) is the etiological agent of Kaposi’s sarcoma (KS), a 
lympho-angioproliferative disease present in four different variants among the 
population: 1) Classic KS, 2) AIDS-Associated KS, 3) Endemic (African) KS and 4) 
Iatrogenic KS. To avoid the interference of factors related to the other variants of 
KS, we studied patients affected by the classic Mediterranean variant of the 
disease, that is mainly found in aged men of Eastern European and Mediterranean 
origin. HHV-8 has a deep impact on B cells through different mechanisms: 1) 
affecting their development; 2) allowing infected B cells to escape from the control 
of the immune system; 3) triggering clonal B cell proliferation by affecting their cell 
cycle check-points and 4) mimicking cell signals that control cell proliferation. 
Moreover, B cells of peripheral lymphoid organs and blood of cKS patients 
represent a major virus reservoir endowed with the ability to sustain the lytic 
reactivation and dissemination of the virus. Importantly, lymphoproliferative 
disorders of B cell origin, including primary effusion lymphoma (PEL) and 
multicentric Castleman’s disease (MCD), can occur concomitantly with cKS, 
confirming the existence of a deep pathogenetic linkage between these 
malignancies. The persistence of HHV-8 infection is the result of a delicate balance 
between immune control, viral latency, viral reactivation and persistent replication. 
However, only a minor proportion of infected hosts eventually develop 
malignancies due to immune breakdown. Thus, despite the high prevalence of 
HHV-8 infection in the European population (24.1% in Italian population), the 
majority of HHV-8-positive subjects do not develop clinically evident malignancies.  
To better understand the role of B cells in chronic HHV-8 infection and associated 
malignancies, we first characterized peripheral B cells in HHV-8 positive patients 
with or without cKS compared to healthy controls by flow cytometry.  Peripheral B 
cells were counted, their different subsets were characterized in depth and 
functional assays were performed to test their state of activation, spontaneous 
apoptosis and proliferation rate.  
In the second part of this study we investigated whether the chronic HHV-8 
infection in B cells could alter the functionality of these cells and particularly may 
impact on humoral responses to antigenic stimulation. To this purpose, we 
assessed the protective efficacy and safety of licensed influenza vaccination in the 
same patients. The advantage of this T-dipendent stimulation relies on the fact that 
influenza vaccination is a common practice of cKS patients, as cKS mainly occurs 
in the elderly, when influenza vaccination is recommended because people aged 
65 and older are at a higher risk of debilitating complications, hospitalizations and 
deaths from influenza. To assess the protective efficacy, we measured the 
antibody response using standard parameters: seroconversion, seroprotection and 
GMT. Also, we evaluated anti-nuclear antibodies (ANA) levels in the cKS patients 
sera to determine if autoreactive B cells, occuring frequently in transitional and MZ-
like B cell developmental stages, could be activated by the vaccination. 
Moreover, we monitored HHV-8 plasma viral load to evaluate whether any 
progression of the disease occured after influenza vaccination; side effects were 
monitored through a daily diary card and finally B cell subpopulations were 
evaluated after vaccination. 
To our knowledge, this is the first study that describes altered B cell homehostasis 
in HHV-8 infected subjects and evaluates the benefit of influenza vaccination in  
KS patients; this observation may broaden our understanding of the complex 
interplay between viral and immune factors leading HHV-8-infected individuals to 
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develop HHV-8-associated malignancies. Moreover, the second part of this study 
demonstrates that influenza vaccination is effective and safe in cKS patients 
despite their B cell alterations. This is relevant because annual influenza 
vaccination may be particularly recommended for cKS patients considering their 
advanced age and comorbidity. 
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3. Materials and Methods  
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3.1 Patients and Controls 
All cKS patients enrolled in this study were followed in the Institute of 
Dermatological Sciences of the Fondazione IRCCS Ospedale Maggiore Policlinico,  
Mangiagalli e Regina Elena. The mean age at the time of the first observation was 
70.6 years. Approximately 40 % of the patients already had a diagnosis of KS 
when they were referred to Department for staging and, if required, treatment. 
Once the clinical and histological diagnosis of KS had been made, the patients 
underwent the following protocol: clinical photography; physical evaluation, 
including a careful evaluation of the main lymph nodal sites (in the case of an 
increase in nodal volume, the patients were asked to undergo lymph node 
ultrasonography and, if necessary, biopsy); routine blood chemistry examinations 
and HIV test; HHV8 test (serology by immunoperoxidase); chest X-ray; ENT 
examination to evaluate pharyngo-oral sites; esophagogastroduodenoscopy and, if 
necessary, biopsy; rectosygmoidoscopy, except in the case of patients with angina 
pectoris, arrhythmias (even if treated), severe respiratory insufficiency, untreated 
severe arterial hypertension or previous vascular accidents (all of these patients 
are given an opaque clyster with a double contrast medium despite the diagnostic 
limitations of the procedure); bronchoscopy and bone marrow biopsy, performed 
only in patients whose overall clinical data suggested possible pulmonary or bone 
marrow involvement. All patients had histologically confirmed diagnosis of KS, 
were positive for anti-HHV-8 antibody and negative for HIV. The selection of 
patients affected by the classic variant of the disease was aimed to avoid the 
confounding effects of HIV-coinfection or immunosuppressive therapy that are 
present in the other clinical variants of KS. Patients in systemic chemotherapy were 
excluded. Staging was performed in accordance with our classification that takes 
into account the prevalent type of lesions, localization, clinical behavior, evolutive 
pattern, and presence of complications [113]. Age- and sex-matched healthy 
subjects were included as controls. Ethics approval was obtained from the local 
Institutional Review Committee, and a signed informed consent was obtained from 
all participants. An accurate description of all clinical characteristics of cKS patients 
and control enrolled for each parts of this study will be reported in result section. 
 
3.2 Sample preparation, staining and flow cytometry for B cell 
characterization 
Sodium-citrate peripheral blood (PB) sample obtained from all individual enrolled 
were processed within 6 hours after blood withdrawal. 100 µl of PB were washed 
two times in PBS plus 1% bovine serum albumin (BSA), and the incubated with 
fetal bovine serum (FBS) for 30 min at 37°C. Then PB were incubated for 30 min 
with with the following antibodies: FITC-conjugated anti-human IgD (Serotec), 
kappa light chain (Miltenyi-Biotec) or CD86 (BD); PE-conjugated anti-human IgM 
(Serotec), lambda light chain (Miltenyi), CD80 (BD), CD38 (Dako) or HLA-DR 
(Caltag); PerCP-Cy5.5-conjugated anti-human CD19 (BD); PE-Cy7-conjugated 
anti-human CD20 (eBiociences, San Diego, CA), APC- conjugated anti-human 54 
CD5 (BD) and APC-Cy7- conjugated anti-human CD27 (eBiosciences). After 
incubation, erythrocytes were lysed using by incubation with ammonium chloride 
for 10 min. All operations were done at 4°C in the dark. Data acquisition and 
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analysis was performed on a FACSCanto flow cytometer (BD) using a FACSDiva 
software (v6.1) immediately after staining. As isotype controls were not used, those 
cells that did not express a certain marker were considered as negative control for 
positive cells. Lymphocytes were gated on forward (FSC) vs side scatter (SSC) plot 
and B lymphocytes were identified as cells CD19+ and/or CD20+. 150,000 events 
were routinely collected to visualize and gate on this population.  
 
3.2.1 Identification of B cell subsets in the peripheral blood 
B cells were identified as CD19+ cells and further gated based on their CD27 
surface expression. Gated on CD27- B cells, transitional and pre-naı¨ve B 
lymphocytes were identified as CD5+CD38hi and CD5+CD38int cells, respectively. 
Gated on CD27-CD5- B cells, naı¨ve and CD27+ memory B lymphocytes were 
identified as IgD+IgM+ and IgD-IgM- cells, respectively. Gated on CD27+ B cells, 
switched memory, IgM-only memory and MZ-like B lymphocytes were identified as 
IgD-IgM-, IgD-IgM+ and IgDloIgM+ cells, respectively. 
 
 
 
 
 
 
 
Figure 6. Gating strategy for the identification of B cell subsets in the peripheral 
blood. 
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3.2.2 Assessment of spontaneous apoptosis of B cell subsets 
The sensitivity of B cell subsets to spontaneous apoptosis was evaluated in 
cultured cells. Isolated PBMCs from 6 cKS patients and 6 HHV-8-seronegative 
healthy controls were cultured in 24-well plated for 24 h in RPMI 1640 (Euroclone, 
Wetherby, UK) containing 10% fetal calf serum (Gibco, Invitrogen Co., Carlsbad, 
CA, USA) and incubated in a 5% CO2 incubator at 37°C for 24 hours. Cells were 
harvested and stained for flow cytometric analysis using an annexin-V APC 
apoptosis detection kit (BD Pharmingen, San Jose, CA, USA) in combination with 
anti-CD19-PerCP-Cy5.5, anti-CD27-PE (BD Biosciences) and anti-IgD-FITC 
(Serotec). Apoptotic cells were identified as annexin-V + cells gated on different B 
cell subsets.  
 
3.2.3 Ex vivo Ki67 staining 
PBMCs from 6 cKS patients and 6 HHV-8-seronegative healthy controls were 
stained for flow cytometric analysis with anti-CD19-PerCP-Cy5.5 anti-CD27-PE 
(BD Biosciences). Samples were then fixed, permeabilised and stained for the cell 
cycleassociated antigen Ki67 (FITC-labeled B56; BD Biosciences), using the 
Leucoperm Reagent (AbD Serotec), according to the manufacturer’s instructions. 
Cells that had recently divided were identified as Ki67+ cells and provided an 
estimate of the in vivo cell turnover. 
 
3.2.4 Isolation of human B cells 
B lymphocytes were isolated from 7 cKS patients and 6 HSP controls, chosen 
among subjects with B cell count either over the 75th percentile or under the 25th 
percentile calculated for each group. Peripheral blood mononuclear cells (PBMCs) 
were obtained by Ficoll density gradient centrifugation (Ficoll-Hypaque Pharmacia 
Biotech AB, Sweden). CD19+ cells were purified using immunomagnetic selection 
with mini-MACS cell isolation Kit (Milteny-Biotec) according to the manufacturer’s 
instructions. Total PBMCs, B cells and non-B cells were further processed for 
virological analyses. 
 
3.2.5 Assessment of HHV-8 infection in isolated cells 
Isolated PBMCs, B cells and non-B cells from 7 cKS patients and 6 HSP controls 
were tested for the presence and load of HHV-8 DNA sequences. Briefly, DNA was 
extracted from at least 2x105 cells, and HHV-8 viral load was measured by 
quantitative real-time polymerase chain reaction (PCR), and results were reported 
as gEq/105 cells.  
 
3.2.6 IL-6, IL-7 and BAFF measurement in plasma samples 
Plasma samples were obtained under sterile conditions from single donors. The 
amounts of plasmatic IL-6, IL-7 and BAFF were determined by ELISA kits from 
R&D Systems (Minneapolis, MN). All individual steps were performed according to 
the manufacturer’s instructions. 
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3.2.7 Immunogenicity assessment 
Serum samples were assessed for HAI antibodies to each hemagglutinin of the 
H1N1, H3N2 and B strains contained in the vaccine, using a standard microtiter 
assay, as previously described (Grilli et al., 1997; Pregliasco et al., 2001). HAI 
antibody titers that were below the detection limit (i.e., <1:10) were assigned a 
value of 1:5. The co-primary immunogenicity outcomes were: a) the proportion of 
subjects with antibody titer ≥1:40 (seroprotection rate); b) the proportion of subjects 
with either a prevaccination titer ≤1:10 and a postvaccination titer ≥1:40 or a 
prevaccination titer  ≥1:40  and a minimum 4-fold increase in postvaccination titer 
(seroconversion rate); c) the geometric mean titer (GMT); and d) the geometric 
mean of the within-subject ratios of pre- and postvaccination reciprocal antibody 
titers (GMT increase).  
 
3.2.8 Safety assessment 
At first visit, enrolled subjects were given a diary card containing a list of solicited 
adverse events and their grades. On the immunization day, subjects were 
observed at the study site for a period of 30 min after vaccination to detect any 
immediate adverse reactions. For the next 7 days, subjects were educated to 
record the severity of solicited local and systemic adverse events, axillary 
temperature and concomitant medications in the diary card. Subjects used a 
standard scale to grade adverse events .  
 
3.2.9 Determination of plasmatic HHV-8 DNA and anti-HHV-8 
antibodies 
cKS patients underwent measurement of plasmatic HHV-8 DNA before, and  4 and 
12 weeks after vaccination. HHV-8 DNA was quantified by HHV-8 Q-PCR Alert Kit 
(Nanogen Advanced Diagnostics, Milan, Italy), according to the manufacturer’s 
instructions. Results were expressed in genome Equivalents (gEq). Anti-HHV-8 
specific IgG antibodies were tested in serum samples using a commercial 
immunofluorescence assay (HHV-8 IgG IFA, Biotrin, Ireland).  
 
3.2.10 ANA testing 
ANA were monitored in the sera before and after immunization by a standard 
indirect immunofluorescence technique on Hep-2 cells (Virgo ANA-Hep-2 IgG Kit, 
Hemagen Diagnostics Inc, Columbia, MD). ANA titer of 1:80 or higher was 
considered positive. 
 
3.2.11 Statistical Analysis 
For comparison between B cell subpopulations, data are presented as mean ± SE. 
Comparisons of samples to establish the statistical significance of difference were 
determined by the Student t test for independent samples. The Mann-Whitney U 
test was also used when indicated. All statistical analyses assumed a 2-sided 
significance level of 0.05. Data analyses were performed with Openstat3 software. 
To assess vaccine immunogenicity, pre- and post-vaccination HAI antibody titers 
were compared within each group using Wilcoxon signed-rank tests. For 
comparison between patients and controls, differences of HAI antibody titers were 
tested by use of the Mann-Whitney U test; proportions were compared by use of 2 
tests and Fisher’s exact tests, as appropriate. All analyses were performed in 
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GraphPad Prism 4.03 (GraphPad Software, San Diego, CA), using a cutoff of P < 
.05 for 2-tailed tests. 
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4. Results 
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4.1 Characterization of b lymphocytes and their subpopulations 
in cks patients 
4.1.1 Clinical characteristic of cKS patients 
 
Forty-seven cKS patients were included in the study, 38 males and 9 females, 
mean age 72 years (range 49-95). All patients had histologically confirmed 
diagnosis of KS, were positive for anti-HHV-8 antibody and negative for HIV. 
Staging was performed in accordance with our classification that takes into account 
the prevalent type of lesions, localization, clinical behavior, evolutive pattern, and 
presence of complications. Patients in systemic chemotherapy were excluded. B 
cells characterization was performed at a single time point on fresh peripheral 
blood samples; staging at this time is reported in Table 3. Forty-three age- and sex-
matched HHV-8-seronegative healthy subjects were included as controls. Ten age- 
and sex-matched HHV-8-seropositive controls without KS were also enrolled. None 
of the subjects had suffered from chronic inflammatory, autoimmune and cancer 
disease other than KS, nor they had clinically evident infections. Peripheral blood 
samples were obtained by venipuncture and collected into sodium citrate 
Vacutainer tubes (Becton Dickinson, San Jose, CA, US). Ethics approval was 
obtained from the local Institutional Review Committee, and a signed informed 
consent was obtained from all participants. 
 
Table 3. Clinical characteristics of patients with cKS
Characteristics Healthy controls cKS patients
No. of patients 43 47
Age, yra 74.4 ± 5 72.2 ± 1.4
Sex, no. 
  Male 39
  Female 8
KS stageb, no. 
  I: maculo-nodular
    A 15
    B 14
  II: infiltrative
    A 4
    B 7
  III: florid
    A 1
    B 3
  IV: disseminated
    A 0
    B 3
aMean ± standard error. 
bcKS patients were classified according to our classification that takes into account the prevalent
 type of lesions, localization, clinical behaviour, evolutive pattern and presence of complications.
A = slow evolution; B = rapid evolution; rapid denotes an increase in the total number of nodules
/plaques or in the total area of plaques in the three months following the last examination. 
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4.1.2 Absolute number of total B cells and their subpopulations in cKS 
patients 
 
4.1.2.1 Absolute number of total B cells 
 
We examined the number and the frequency of B cells and their subpopulations in 
the peripheral blood of 47 cKS patients compared with 43 healthy controls, by 
using 6-color flow cytometry. B lymphocytes were identified as cells positive for 
staining with anti-CD19. As show in Figure 7, B cells were increased in cKS 
patients (234 ± 35 vs 129 ± 13 cells/µl, cKS patients vs healthy controls; P < 0.05). 
The frequency of B cells within lymphocytes in healthy aged controls was 6.7% ± 
0.5, as expected and it was significantly higher in cKS patients (10.9% ± 1.1; P < 
0.001). 
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Figure 7: Absolute number  of circulating B cells in control subjects (white) and in 
cKS patients (grey). Data presented as mean ± SE. The statistical significance was 
determined by the two-tailed Mann–Whitney test. 
 
 
 
 
 
 
4.1.2.2 Absolute number of preimmune/natural effector and antigen-
experienced B cell compartment 
 
To more precisely define the phenotype of the expanded populations we examined 
the distribution of B cells along the various steps of peripheral B cell maturation 
and differentiation. Gated on B cells, the expression of CD27 was used to roughly 
discriminate between naïve (CD27-) and memory (CD27+) B cells. As shown in 
Figure 8, the analysis of CD27- and CD27+ compartments showed that the absolute 
number of CD27- B lymphocytes was significantly higher in cKS that controls (172 
HSN controls
cKS patients
 47 
± 24 vs 86 ± 9 cells/µl; P < 0.002), while there was no difference between the 
absolute number of CD27+ B cells (59 ± 12 vs 43 ± 6 cells/µl, P=ns). This resulted 
reflected the significant increase of the frequency of CD27- (73.6% ± 2.1 vs 67.1% 
± 2.6; P < 0.05).  
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Figure 8: Absolute number of circulating B cells in control subjects (white) and in 
cKS patients (grey). Data presented as mean ± SE. The statistical significance was 
determined by the two-tailed Mann–Whitney test. 
 
 
 
 
 
Within CD27- cells, we defined transitional B cells, pre-naïve B cells, unswitched 
naïve B cells and CD27- memory B cells. The absolute number of transitional (15 ± 
2 vs 5 ± 2 cells/µl) , pre-naïve (27 ± 4 vs 7 ± 1 cells/µl) and unswitched naïve B 
cells (98 ± 15 vs 66 ± 10 cells/µl), all belonging to the  preimmune/natural effector 
B cell compartment, resulted significantly higher in cKS patients than healthy 
controls (P < 0.002, P < 0.0001 and P < 0.05, respectively). The only CD27- B cell 
subset that was not expanded in cKS patients was represented by CD27-, isotype-
switched, memory B cells (14 ± 2 vs 17 ± 2 cells/µl). 
Within CD27+ cells, we defined switched memory, IgM memory and MZ-like cells. 
Among CD27+ lymphocytes, only the subset of MZ-like B cells, a subpopulation 
that has been suggested to generate a preimmune repertoire was markedly 
expanded in cKS patients (42 ± 12 vs 17 ± 2 cells/µl; P < 0.05), while switched (19 
± 2 vs 24 ±  4 cells/µl) and IgM memory B cells (2 ± 0.3 vs 2 ± 0.4 cells/µl), all 
belonging to the antigen-experienced B cell compartment, did not change (Figure 
9). Similar results were observed when the frequency of B cell subpopulations 
rather than their absolute count were considered. 
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cKS patients
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Figure 9: Absolute number of circulating B cell subsets  in control subjects (white) 
and in cKSpatients (grey). Data presented as mean ± SE. The statistical 
significance was determined by the two-tailed Mann–Whitney test. 
 
 
 
 
 
 
4.1.2.3 B cells spontaneous apoptosis and in vivo turnover in cKS patients 
and healthy controls 
 
To futher understand the mechanisms possibly involved in the expansion of distinct 
B cell subsets in cKS patients, we examined two parameters that can impact on the 
size of cell populations and that can be measured in the periphery: cell apoptosis 
and cell turnover. 
The level of spontaneous apoptosis of cultured B cells was detected by annexin V 
binding. We abserved that apoptosis was significantly lower in cKS patients than in 
healthy donors (P < .05) (Figure 10 and 11). 
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Figure 10: Representative flow cytometric analysis showing annexin V binding 
gated on total B cells, CD27-, MZ-like and switched memory B cells; comparison 
between one healthy control (HC) (upper row) and one cKS patients (lower row). 
 
 
 
 
In Figure 11, we observed significantly lower apoptosis in CD27- B cells in cKS 
patients than healthy controls (P < 0.05), in particular in transitional, pre-naïve, 
naïve and CD27+ IgDlo, consisting in MZ-like B cells (P < 0.02). Accordingly, CD27+ 
IgD- cells that mainly consist of switched memory B cells did not vary between cKS 
patients and healthy controls. 
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Figure 11: B cells from cKS patients (grey) showed significantly lower annexin V 
binding than B cells from HCs (white). Data shown as mean ±  SE. P-values 
calculated using the Student t test for independent samples. 
 
 
 
 
 
 
To estimate the in vivo turnover of B cells, we analyzed the expression of Ki67, a 
nuclear antigen that identifies recently divided cells. A representative flow 
cytometric analysis is shown in Figure 12. The proportion of Ki67 + cells was 
higher within CD27+ than CD27- B cells, as expected. As shown in Figure 13, the 
percentage of Ki67+ cells among total B cells, as well as CD27- and CD27+ B cells 
did not differ between cKS patients and healthy controls. 
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Figure 12: Representative flow cytometric analysis showing Ki67 binding gated on 
total B cells, CD27+ and CD27+ B cells, as indicated; comparison between one 
healthy control (upper row) and one cKS patient (lower row). 
 
 
 
 
 
Figure 13: The proportion of Ki67+ cells 
within total B cells, CD272 and CD27+ B cells did not differ between cKS patients 
(grey) and healthy controls (white). Data shown as mean ±  SE. P-values 
calculated using the Student t test for independent samples. 
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4.1.3 Expression of activation and maturation markers on B cells 
 
To assess the activation state of B cell subsets, we investigated expression of 
various activation markers, including CD80, CD86, and HLA-DR. Moreover, we 
evaluated other cellular markers as CD20 expression, a putative calcium channel 
that is down-regulated upon B cell activation and that is expressed by the majority 
of human B-cell lymphomas and leukemias. All the data are expressed as MFI. 
 
Expression of CD80 (264 ± 22 vs 385 ±29, cKS patients vs healthy controls; P < 
0.005) and CD86 ( 111 ± 4 vs 142 ± 6; P < 0.01) was examined on CD19+ B cells, 
CD27- immature-naïve B cells (CD80: 145 ± 17 vs 239 ± 27, P < 0.01; CD86: 103 ± 
5 vs 122 ± 7, P < 0.05), and CD27+ memory B cells (CD80: 666 ± 33 vs 742 ± 35, 
P = ns; 144 ± 5 vs 156 ±  5; P = ns) and were lower in cKS patients compared with 
healthy controls; also the expression of HLA-DR molecules tended to be lower on 
B cells from KS patients than healthy donors (1627 ± 115 vs 1794 ± 177, P = ns), 
on CD27- cells (1779 ± 142 vs 1727 ± 196, P = ns) and on CD27+ cells (1549 ± 106 
vs 1860 ± 165, P = ns). 
B lymphocytes from cKS patients expressed higher surface levels of the molecule 
CD20 even if we considered total B cells (8082 ± 556 vs 5292 ± 388; P < 0.001), 
CD27- cells  (6478 ± 548 vs 4503 ± 343; P < 0.001 ) and CD27+ cells (11202 ± 667 
vs 6901 ± 548; P < 0.001 ), (Figure 14). 
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Figure 14: Expression of activation markers on B cells in control subjects (white) 
and in cKS patients (grey). Data presented as mean ± SE. The statistical 
significance was determined by the two-tailed Mann–Whitney test. 
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4.1.4 Frequency of monoclonal B cell expansion 
 
Due to the involvement of HHV-8 infection in lymphoproliferative disorders, we 
further characterized B cells to analyse the frequency of monoclonal B cell 
expansions in cKS patients.  
We analyzed the immunophenotype of B cells and evaluated the k/λ light chain 
ratio in cKS patients and healthy controls, according to the diagnostic criteria 
proposed for monoclonal B lymphocytosis (MBL). In particular, CLL-like MBL was 
defined based on the distinct CD5brightCD20dim expression pattern on CD19+ B cells. 
Atypical CLL-like and non-CLL-like MBL were defined based on the occurrence of 
an unbalanced k/λ ratio (more than 3:1 or less than 1:3) within CD5+ and CD5- B 
cells, respectively. 
On the base of this strategy, we identified MBL in 4 of 43 healthy controls (9.3%; 1 
CLL-like, 2 atypical CCL-like and 1 non-CLL-like MBL. Moreover, we identified MBL 
in 2 of 47 cKS patents (4.3%; 1 CLL-like and 1 non-CLL-like MBL). k light chain 
restriction was observed in 2 MBL clones (2 HCs), λ light chain restriction in 2 
clones (1 healthy control and 1 cKS patient), while negativity for both light chains 
was evident in the remaining 2 cases (Figure 15). 
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Figure15: Representative flow cytometric analysis showing CLL-like MBL, atypical 
CCL-like and non-CLL-like MBL; comparison between one HC (upper row) and one 
cKS patient (lower row). 
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4.1.5 IL-6, IL-7 and BAFF plasmatic levels 
To evaluate whether the changes in B cells observed in cKS patients could be 
affected by cytokines involved in the growth and differentiation of B lymphocytes, 
we measured the plasmatic levels of IL-6, IL-7 and BAFF in our samples. 
Low levels of IL-6 were found in 67% of the cKS patients (mean ± SE: 7.9 ± 1.7 
pg/ml) and 30% of the healthy controls (4.9 ±1.9 pg/ml) and did not significantly 
differ between groups. Also the plasmatic levels of IL-7, detected in all the 
samples, showed no differences between cKS patients and controls (8.6 ± 1.0 and 
7.1 ± 0.7 pg/ml, respectively). Also, Baff did not change between cKS patients and 
controls (0.91 ± 0.05 and 1.17 ± 0.09 ng/ml, respectively). No correlation was 
observed between the number of B cells or their subsets and the plasmatic levels 
of cytokines.  
 
 
4.1.6 Changes in B cells from cKS patients and HSP controls do not 
correlate with HHV-8 load 
We analyzed possible correlations between the number of B cells or their subsets 
and the viral gEq measured in plasma. No correlation was observed between the 
count of either total, CD27-, CD27+ B cells or their subsets and plasmatic HHV-8 
gEq. To investigate whether B cell infection in correlated with the expansion of B 
cells and their subsets, we selected 7 cKS patients and 6 HSP controls with B cell 
count either over the 75th percentile or under the 25th percentile calculated for each 
group, and determined the presence of HHV-8 gEq in their PBMCs and isolated B 
cell and non-B fractions. B cells from 6 of 7 cKS patients and from 3 of 6 HSP 
controls were found to harbor HHV-8 DNA sequences (6–475 HHV-8 gEq/105 
cells). HHV-8 DNA was detected in B cells from 5 of 7 subjects with B cell 
expansion and from 4 of 6 subjects without expansion; moreover, there is no 
difference in the number of HHV-8 gEq of individuals with or without B cell 
expansions (Table 4). Indeed we found no correlation between B cell viral infection 
and B cell changes. Also, no correlation was observed between anti- HHV-8 
antibody titres and B cell changes. 
 
 57 
Table 4. HHV-8 DNA in isolated peripheral blood mononuclear cells, B cells and non-B cells from patients with cKS 
and HHV-8 seropositive healthy controls according to their changes in B cell count 
patient gender age KS stage
b
percentile 10
3
/mmc P B MC nonB B
KS 5 M 51 1A <25th percentile 491,16 <5 <5 5
KS 4 M 69 1B >75th percentile 355,41 11 <5 6
KS 1 M 69 2A >75th percentile 302,59 244 98 475
KS 2 M 66 2A >75th percentile 277,78 < 5 < 5 10
KS 3 M 74 1A >75th percentile 90,83 < 5 < 5 15
KS 7 M 75 1B <25th percentile 69,38 < 5 < 5 < 5
KS 6 M 62 3A <25th percentile 43,88 <5 < 5 20
HHV-8+ 1 >75th percentile 297,79 < 5 < 5 < 5
HHV-8+ 3 >75th percentile 249,67 19 < 5 15
HHV-8+ 2 >75th percentile 244,16 < 5 < 5 < 5
HHV-8+ 4 <25th percentile 144,66 < 5 < 5 11
HHV-8+ 5 <25th percentile 125,46 27 <5 294
HHV-8+ 6 <25th percentile 107,26 < 5 < 5 < 5
B cell count gEq/10
5
cells
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58 
4.1.7 Absolute number of total B cells and B cell subpopulation in 
HHV-8 seropositive controls 
To investigate whether the changes observed in circulating B cells from cKS 
patients were dependent on HHV-8 infection or whether they were related to the 
presence of the tumor, we included in our study ten age- and sex-matched HHV-8 
seropositive (HSP) controls without KS. We analyzed the number of B cells and 
their subsets and the state of activation of B cells in HSP subjects compared with 
healthy controls and cKS patients. As reported in Table 5, HSP controls showed 
changes in B cells that were similar to those observed in cKS patients. In particular, 
HSP had higher number of total B cells than healthy controls (P<0.01); similarly to 
what we observed in cKS patients, the expansion of B cells in HSP controls was 
restricted to the CD27- population, that was increased in HSP compared with 
healthy controls (P<0.002). As observed in cKS patients, HSP controls showed 
expanded transitional, pre-naı¨ve, naı¨ve and MZ-like B cells, while the number of 
IgM-only, switched and CD27- memory B cells was unaffected.  
We further investigate B cells phenotype in HSP controls; we analyzed B cell 
expression of CD80 and CD86 and observed that MFI of both costimulatory 
molecules was significantly lower on B cells from HSP than healthy controls 
(P<0.02 and P<0.05 for CD80 and CD86, respectively). 
 
 
Table 5: Analysis of B cells from healthy HHV-8-seropositive (HSP) compared with 
HHV-8-seronegative controls and cKS patients. 
healthy controls cKS patients HHV8+ seropositive controls p values p values
n=43 n=47 n=10  HSP healthy controls  HSP vs KS
B cells (cells/ L) 128,53 ± 12,85 234,41 ± 35,28 187,19 ± 19,26 0,0100 ns
CD27- B cells (cells/ L) 85,56 ± 9,11 172,38 ± 24,30 140,6 ± 17,13 0,0020 ns
CD27+ B cells (cells/ L) 42,97 ± 5,79 58,54 ± 12,21 50,37 ± 9,12 ns ns
Preimmune pools 
transitional (cells/ L) 5,29 ± 2,03 14,67 ± 2,03 8,39 ± 1,56 0,0010 ns
pre-naive (cells/ L) 6,58 ± 1,35 27,15 ± 3,73 15,46 ± 2,89 0,0100 ns
naive (cells/ L) 65,7 ± 9,6 98,24 ± 14,87 88,93 ± 12,81 0,0500 ns
MZ-like (cells/ L) 16,59 ± 2,38 42,12 ± 12,45 22,39 ± 4,17 0,0500 ns
Antigen-experienced pools
IgM-only memory (cells/ L) 1,96 ± 0,38 1,68 ± 0,26 1,86 ± 0,42 ns ns
switched memory (cells/ L) 24,35 ± 3,54 14,28 ± 2,17 25,5 ± 5,69 ns ns
CD27- memory (cells/ L) 16,95 ± 2,15 19,03 ± 2,23 13,11 ± 2,43 ns ns
B cell immunophenotype
CD80 (MFI) 394,28 ± 29,15 273,24 ± 22,94 272,50 ± 35,86 0,0200 ns
CD86 (MFI) 139,02 ± 6,31 116,73 ± 4,83 113,78 ± 9,63 0,0500 ns
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4.2 Efficacy and safety of seasonal influenza vaccination in cKS 
patients 
4.2.1 Clinical characteristics of vaccinated cKS patients 
Forty-six cKS patients and 44 healthy controls were enrolled into the study. Their 
demographic characteristics at enrollment are reported in Table 6. KS staging was 
performed in accordance with our classification that takes into account the 
prevalent type of lesions, localization, clinical behavior, evolutive pattern, and 
presence of complications [42, 265]. All patients were positive for anti-HHV-8 
antibody and negative for human immunodeficiency virus (HIV). Patients in 
systemic chemotherapy were excluded.  None of the applicants had acute febrile 
illness or signs of severe acute illness at the time of vaccination, a history of 
anaphylaxis due to vaccine components, or other inappropriate condition to receive 
vaccination, nor they had suffered from autoimmune and cancer disease other than 
KS. All patients and controls reported receiving influenza vaccine in the previous 
year. 
 
 
 
Table 6. Baseline characteristics of study participants
Characteristic healthy controls cKS patients
(n = 44) (n = 46)
Male sex 36 (82) 38 (85)
Age 74 ± 5 74 ± 6
KS stage
   I: maculo-nodular 
      A: slow 18
      B: rapid 14
   II: infiltrative
      A: slow 3
      B: rapid 6
   III: florid
      A: slow 1
      B: rapid 2
   IV: disseminated
      A: slow 0
      B: rapid 2
   NOTE.  A = slow evolution; B = rapid evolution.
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4.2.2 Immunogenicity 
Serum samples were assessed for HAI antibodies to each hemagglutinin of the 
H1N1, H3N2 and B strains contained in the vaccine, using a standard microtiter 
assay HAI antibody titers.  
Titers below the detection limit (i.e. <1:10) were assigned a value of 1:5. Geometric 
mean titers (GMTs) and seroprotection rates (defined as HI titers >1:40) were the 
main outcome measures. Seroconversion was defined by a postvaccination HI titer 
of at least 1:40 combined with at least a four-fold increase in titer in accordance to 
European and international guidance. 
The co-primary immunogenicity outcomes were: a) the proportion of subjects with 
antibody titer ≥1:40 (seroprotection rate); b) the proportion of subjects with either a 
prevaccination titer ≤1:10 and a postvaccination titer ≥1:40 or a prevaccination titer  
≥1:40  and a minimum 4-fold increase in postvaccination titer (seroconversion 
rate); c) the geometric mean titer (GMT); and d) the geometric mean of the within-
subject ratios of pre- and postvaccination reciprocal antibody titers (GMT increase). 
Antibody responses were measured at baseline, 4- and 12 weeks after vaccination. 
Among both cKS patients and controls, seasonal influenza vaccine led to 
significant increases in HAI antibodies to all three strains, with an increase in the 
antibody level against H1N1, H3N2 and B strains of ≥ 4-fold (P < 0.001), (H1N1: 
9.6-fold  vs 7,5-fold; H3N2: 4.4-fold vs 6.0-fold; B 8.2-fold vs 15.5-fold, cKS patients 
vs healthy controls, respectively). 
At baseline, seroprotection rate was comparable between cKS patients and healthy 
controls for H1N1 (57% vs 59%) and H3N2 (39% vs 55%) but not for B: cKS 
patients showed higher rate (48% vs 27%) of seroprotection. After 4- and 12 weeks 
post vaccination, seroprotection rate was comparable between cKS patients and 
healthy controls for all the 3 antigens (H1N1: 87% vs 77%; H3N2:  65% vs 82%; B: 
83% vs 77%). 
Also, seroconversion rate was similar in cKS patients and healthy controls at any 
time point and for each antigen (4 weeks: H1N1: 74% vs 73%; H3N2:  43% vs 
68%; B: 65% vs 73%; 12 weeks: 57% vs 50%; H3N2: 26% vs 36%; B: 43% vs 
59%). 
The GMT was similar in cKS patients and healthy controls at any time point for 
H1N1 antigen (baseline: 25.5 vs 28.3; 4 weeks: 244.0 vs 212.5; 12 weeks: 114.9 
vs 113.1) but was lower at 4 and 12 weeks in cKS patients for H3N2 antigen 
(P<0.05 and P<0.02, respectively) (baseline: 17.7 vs 32.1; 4 weeks: 77.6 vs 193.3; 
12 weeks: 47.9 vs 106.2) and was higher at baseline and at 4 weeks in cKS 
patients for B antihen (P<0.05 and P<0.02, respectively) (baseline: 27.9 vs 11.3; 4 
weeks: 229.7 vs 175.9; 12 weeks: 122.0 vs 109.6) (Table 7). 
Among cKS patients, no correlation was observed between immunogenicity 
parameters (seroprotection rate, seroconversion rate, GMT or GMT increase) and 
either age, cKS stage or HHV-8 viremia. No correlation was observed between pre- 
and post-vaccination HAI antibodies and any B cell subset. 
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Table 7. Antibody Titers against Seasonal A/H1N1, A/H3N2 and B Virus before and 4 and 12 Weeks 
after Receipt of Seasonal Vaccine in cKS Patients Compared with Healthy Controls.
Virus, antibody healthy controls cKS patients
(n = 44) (n = 46)
A/Brisbane/59/2007 (H1N1) 
   Seroprotection rate
      Prevaccination 59 57
      4 weeks after vaccination 77 87
      12 weeks after vaccination 77 87
   Seroconversion rate
      4 weeks after vaccination 73 74
      12 weeks after vaccination 50 57
   GMT [fold increase] 
      Prevaccination 28.3 25.5 
      4 weeks after vaccination 212.5 [7.5]a 244.0 [9.6]a
      12 weeks after vaccination 113.1 [4.0]a 114.9 [4.5]a
A/Brisbane/10/2007 (H3N2) 
   Seroprotection rate
      Prevaccination 55 39
      4 weeks after vaccination 82 65
      12 weeks after vaccination 82 65
   Seroconversion rate
      4 weeks after vaccination 68 43
      12 weeks after vaccination 36 26
   GMT [fold increase]
      Prevaccination 32.1 17.7 
      4 weeks after vaccination 193.3 [6.0]a 77.6 [4.4]a,b
      12 weeks after vaccination 106.2 [3.3]a 47.9 [2.7]a,c
B/Florida/4/2006 
   Seroprotection rate
      Prevaccination 27 48d
      4 weeks after vaccination 77 83
      12 weeks after vaccination 77 83
   Seroconversion rate
      4 weeks after vaccination 73 65
      12 weeks after vaccination 59 43
   GMT [fold increase]
      Prevaccination 11.3 27.9b 
      4 weeks after vaccination 175.9 [15.5]a 229.7 [8.2]a,c
      12 weeks after vaccination 109.6 [9.7]a 122.0 [4.4]a
   NOTE.  GMT, geometric mean titer
    d χ2 test, for intergroup comparison of seroprotection and seroconversion rates: P  < 0.05
    b
 Mann-Whitney U test, for intergroups comparison of GMT: P < 0.05
    c
 Mann-Whitney U test, for intergroups comparison of GMT: P < 0.02
    a Wilcoxon signed-rank test, for intragroup postvaccination to prevaccination comparison of GMT:  P < 0.001
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4.2.3 Safety 
We evaluated reported symptoms and we found no serious adverse events 
following influenza vaccination. Similar frequencies of solicited local and systemic 
reactions to vaccine were reported in the diary card by cKS patients and controls. 
We considered both local and systemic reactions. The most frequent local reaction 
reported by both cKS patients and controls was pain at the injection site (33% and 
36%, respectively) with or without redness and swelling. Headache and malaise 
were the most frequently reported systemic reactions, reported by 20% and 10% of 
subjects, respectively. Mild elevation of body temperature (37.8°C) was only 
reported by one cKS patient 2 days after vaccination (Table 8). 
 
             Table 8: Reported symptoms after vaccination 
healthy controls cKS patients
n=44 n=46
Local reaction 
Pain at the injection site 36% (16/44) 33% (15/46)
Systemic reactions
Headache and malaise 10% (4/44) 20% (9/46)
Mild elevation of body temperature 0% (0/44) 4% (2/46)  
 
 
4.2.4 HHV-8 virologic rebound 
At baseline, 5 cKS patients (11.6 %) had copy number of HHV-8 genome above 
250 gEq/ml. Following influenza vaccination, a virologic rebound, defined as an 
increase of at least 3-fold from baseline [284] was observed in one of these 
patients and in 3 cKS patients who had undetectable HHV-8 DNA before 
immunization. Virologic rebound was observed 4 weeks after vaccination in 2 
cases and 12 weeks after vaccination in the other 2 cases. None of the 4 patients 
showing virologic rebound experienced a progression of KS lesions within 12 
months starting from vaccine administration.  
 
4.2.5 Anti-HHV-8 titers 
At baseline, all cKS patients had positive anti-HHV-8 antibodies, with titers 1:512 or 
higher. By contrast, all healthy controls were HHV-8 seronegative. Following 
vaccination, 11 cKS patients (25.0%) showed an increase of anti-HHV-8 antibodies 
titer from baseline: 3 patients showed a transient increase 4 weeks after 
vaccination that reverted after 12 weeks; 2 patients showed an increase after 4 
weeks that persisted 12 weeks after vaccination; 6 patients showed an increase 12 
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weeks after vaccination. None of the patients with post- to pre-vaccination increase 
of anti-HHV-8 antibodies showed HHV-8 virologic rebound. 
 
4.2.6 ANA titers 
The percentage of subjects positive for ANA before vaccination were similar among 
cKS patients and controls (15.2% and 22.7%, respectively; Fisher’s exact tests: P 
= ns). Among cKS patients, 5 subjects who were initially negative for ANA became 
positive after immunization (4 subjects after 4 weeks, 1 subject after 12 weeks). 
Among controls, 2 subjects became positive (1 after 4 weeks, 1 after 12 weeks). In 
all but 1 subject, positive ANA was detected 12 weeks after vaccination. Moreover, 
1 patient and 1 control that were initially positive for ANA showed an increased titer 
after vaccination. The post- to pre-vaccination changes in the level of ANA did not 
differ significantly between cKS and healthy controls. No correlation was observed 
between pre- and post-vaccination ANA titers and any B cell subset. 
 
4.2.7 B cell subpopulation homeostasis after influenza vaccination 
We analyzed B cells subpopulations at 4 and 12 weeks post vaccination to 
determine possible changes in their frequency. cKS patients showed a higher 
frequency of CD27- B cells than healthy controls, as previously assessed, in all 
time points; the frequency of CD27- and CD27+ B cells did not vary in all the time 
points, both in healthy control group and in cKS patient group  (Figure 16). 
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Figure 16: Frequency  of CD27- and CD27+ circulating B cells in control subjects  
and in cKS patients at three time points (dark blue= before vaccination; blue= 30 
days after vaccination; light blue= 60 days after vaccination) . Data presented as 
mean ± SE.  
 
 
 
 
 
 
 
We further analyzed B cells subpopulations; as expected, the frequency of 
preimmune/natural effector compartment was higher in cKS patients compared 
to healthy controls at all the three time points. Generally, we did not observed 
any change in the frequency of B cell subpopulations before and after 
vaccination, both in healthy controls and cKS patients, with the exception of 
transitional B cells in cKS patients; indeed, we observed a slight decrease in 
the frequency at 4 and 12 weeks after vaccination compared to the frequency 
before influenza vaccination (6,7% vs 3,6% vs 3,1; P<0.05) (Figure 17). 
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5. Discussion  
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B cells represent the major reservoir of HHV-8, which is the etiologic agent of KS. 
HHV-8 is a good potential candidate as B cell disregulating agent, because it is 
able to influence the fate and function of B cells through a number of viral proteins 
that affect B cell development, allow infected B cells to escape from the control of 
the immune system, and trigger clonal B cell proliferation by affecting B cell cycle 
check-points and by mimicking cell signals that control cell proliferation 
[246,247,248]. In order to better understand the role of B cells in chronic HHV-8 
infection and associated malignancies and whether HHV8-infection may be 
associated with B cell abnormalities, in the first part of our study we characterized 
circulating B cells in patients with cKS by 6-color flow cytometric assay. Moreover, 
to ascertain whether B cell alteration occurring in cKS patients were secondary to 
HHV-8 infection per se, we included a group of healthy HHV-8 seropositive (HSP) 
controls not affected by KS. 
The markers used in the flow cytometric enable the analysis of B cells belonging to 
either preimmune/natural effector compartment or the antigen-experienced 
compartment. Within the preimmune/natural effector compartment, transitional, 
pre-naı¨ve and naı¨ve B cells were identified as cells lacking the expression of 
CD27 and further defined by the expression of CD38, CD5 and/or Ig isotypes [249]. 
MZ-like B cells were identified as CD27+ IgDloIgM+ [250]; these cells are a unique 
population with attributes of both naı¨ve and memory B cells [251]. Within the 
antigen-experienced T helper-dependent compartment, memory CD27+ B cells, 
including IgM-only and switched memory B cells, as well as a subset of CD27+IgD+ 
memory B cells [252] were identified. 
Our results indicated that cKS patients have a significantly higher number of 
circulating B cells than healthy controls. Also, analysis of circulating B cells in HSP 
showed similar levels compared with cKS patients.  
Moreover, the expansion of B cells in cKS patients and HSP was evident in the 
preimmune/natural effector compartment: we observed increased number of 
transitional, pre-naı¨ve, naı¨ve and MZ B cells, although we did not observe an 
increased frequency of monoclonal B cell expansions in our patients, while no 
difference was observed in the antigen-experienced T helper-dependent 
compartment.  
Such B cell perturbation has been reported in other conditions characterized by 
viral chronic infections and autoimmune diseases. In particular, an increase of 
CD27-, naïve B lymphocytes not accompanied by expanded memory cells and 
lacking of B cell activation has been studied in patients with chronic C hepatitis 
[253]. An expansion of circulating immature transitional B cells has been described 
in individuals infected with either hepatitis C virus (HCV) or human 
immunodeficiency virus (HIV) [254,255]. These observations may suggest that 
diverse viral infections, all characterized by frequent chronicization, share the 
ability to perturb the homeostasis of B lymphocytes by promoting the accumulation 
of non-memory B cell subsets. Whether the virus-induced changes of B cells may 
represent a common strategy acted by diverse viruses to elude the control of B 
cell-mediated immune responses remains an intriguing possibility that may deserve 
to be further investigated. Expansion of transitional and MZ like B cells 
compartment was described in autoimmune disease such as Sjogren Syndrome 
[256]. We measured the level of autoantibodies and BAFF level in cKS patients 
and HSP, that are often correlated with the expansion of transitional and MZ B cells 
in autoimmune diseases, but we didn’t observed increased levels compared to 
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healthy controls. We can hypotize a local increase of BAFF in lymphopoietic 
organs, not measurable in the serum; other factors known to affect B cell 
maturation IL-5 and IL-21 [285, 286], were not investigated in this study. 
We further analyzed the expression of activation markers on B cell subpopulations. 
Our results demonstrated that B cells in cKS patients expressed lower levels of 
activation markers CD80 and CD86 either on CD27- or CD27+ B cells, suggesting 
that there is no correlation between the expansion observed in the 
preimmune/natural effector compartment  and the state of activation observed in 
the total B cell population of HHV-8 infected subjects. Also, the surface expression 
of CD20, a putative calcium channel that is downregulate upon B cell activation 
and that is expressed by the majority of human B cell lymphomas and leukemias 
[257,258], on the contrary is higher on both CD27- and CD27+ B cells of cKS 
patients and HSP compared to healthy controls, according to their state of low 
activation. 
Moreover, we analyzed alternative mechanisms that possibly could promote the 
accumulation of B cells in the preimmune/natural effector compartment: 
spontaneous apoptosis and in vivo turnover. The most important finding was the 
increased resistance to spontaneous apoptosis that is specific of the 
preimmune/natural effector compartment while we didn’t observe any difference in 
the rate of proliferation between the two compartments.  
It is well known that multiple HHV-8 gene products are able to promote survival of 
infected cells by increasing resistance to apoptosis, including latency-associated 
nuclear antigen (LANA), viral Flice-inibitory protein (v-Flip) and the viral chemokine 
ligands v-CCL1 and v-CCL2 [259] but the hypothesis of direct effects of HHV-8 is 
unlikely due to the low frequency of infected cells.  
So we hypothesized that HHV-8 infection may perturb the homeostasis of B cells in 
an indirect way, maybe through some mediators that could affect proliferation, 
differentiation, traffiking and lifespan. Among other factors, IL-6 of either viral or 
human origin may represent a good candidate factor, as it is a well defined B cell 
growth factor [260] centrally involved in KS. Its antiapoptotic effects on B cells were 
proven [261,262] and it is expressed by a multitude of cell types upon HHV-8 
infection such as lymphocytes [263,264]. Also, we previously demonstrated that 
dendritic cells from cKS patients produce higher amounts of IL-6 than controls 
[265]. The lack of increased human-IL-6 levels in our patients and the lack of 
correlation between circulating IL-6 and B cell changes cannot rule out either the 
involvement of v-IL-6 or a local effect exerted by IL-6 within lymphoid tissues. 
Cell fate during early B-cell development is also influenced by IL-7, which have a 
central role in controlling the survival, proliferation and differentiation of B cells 
[266]; also, increased serum level of IL-7 reactive to CD4+-T cells lymphopenia was 
proposed to explain the disturbance of peripheral blood B cell homeostasis during 
pathological condition such as HCV infection and HIV infection. We measured IL-7 
in the plasma of cKS patients and HSP but we did not observed increased level, 
suggesting that this factor did not impact on B cell alteration observed in our cKS 
patients.  
In conclusion, in this first part of the study, we provide evidence that HHV-8 chronic 
infection induces an expansion of B cells in the preimmune/natural effector 
compartment but further insight might be gained by additional experiments 
designed to understand the exact mechanism leading expansion on immature B 
cells in cKS patients. 
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In the second part of the study, we investigated whether B cell alterations observed 
in cKS patients may alter the response to influenza vaccination, in terms of clinical 
efficacy, humoral response, safety and B cell homeostasis. The majority of cKS 
patients usually undergo seasonal influenza vaccination due to the fact that cKS 
mainly occurs in the elderly, when influenza vaccination is recommended, as 
people aged 65 and older are at a higher risk of debilitating complications, 
hospitalizations and deaths from influenza [267; 268; 256].  
It is well known that aging affects both humoral immune response and cell-
mediated immunity quantitatively and qualitatively [269]; influenza virus should 
stimulate an antiviral response in both B and T lymphocytes resulting in humoral 
and cell-mediated immunity, respectively. Virus-activated T-cells, through cytokine 
mediators, stimulate B-cells to differentiate and produce antibodies specific for a 
particular vaccine strain and antibody responses to influenza vaccination have 
largely been evaluated by the hemagglutination inhibition assay (HAI). 
We evaluated the immune response to influenza vaccine in cKS patients and we 
observed a significant increase in HAI titers against the three viral strains in both 
patients and controls; we observed some differences in antibody levels between 
the two groups, maybe due to the small sample size, but we can assert that the 
immunogenicity after vaccination was adeguate in both patients and controls, 
according to the European Agency for Evaluation of Medical Products (EMEA) 
criteria for adults ≥ 60 years of age. 
Influenza vaccination often occurs in September through November while influenza 
virus exposures occur well through the end of winter. Therefore, we assessed the 
prolonged effectiveness of influenza vaccine by measuring the seroprotection 
against all three antigens after 3 months from the vaccination and we observed that 
seroprotection persisted, demostrating a lasting response to vaccination as already 
demonstrated [270].  
According to the serologic responses that were similar in cKS patients and 
controls, during the influenza season an equal number of cKS patients and controls 
(4 and 4 corresponding to 8.7 and 9.1% of subjects, respectively) reported 
influenza-like illness episodes, defined as temperature ≥37.8°C plus cough or sore 
throat [272]. All the episodes were registered in a a diary card containing a list of 
solicited adverse events and their grades during the course of the study. Due to the 
fact that we enrolled subjects from all the regions of Italy, it was quite impossible to 
documente any adverse event that would be consistent with either influenza 
infection or influenza-like illness by using methods for virus detection such as by an 
influenza-positive nasopharyngeal wash [271]. 
All the patients and controls who experienced influenza-like illness had achieved 
postvaccination seroprotection to at least one viral strain. This is in accordance 
with previous reports that a HAI titer ≥ 40, generally considered predictive of 
protection in adults, may not provide the same level of protection from influenza 
infection in the elderly [273, 274, 275].  
The rate and intensity of reported solicited local and systemic reactions to 
vaccination were similar in cKS patients and controls; the most frequent local 
reaction was pain at the injection site while the most frequent sistemic reaction was 
headache with malaise. This data are in accordance with other studies using 
virosomal influenza vaccines [273].  
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At baseline, we observed an expansion of transitional and other preimmune B 
cells, that represent B cell developmental stages in which autoreactive B cells 
occur more frequently [256]; to assess if a stimulation such as vaccination could 
lead to a autoantibodies production, we measured anti-ANA antibodies in the 
serum. Influenza vaccination induced the production of new autoantibodies in a 
higher, although not significant, proportion of cKS patients (10.9%) than controls 
(4.5%). Importantly, newly synthesized autoantibodies after vaccination had no 
apparent clinical significance as no subject among patients and controls developed 
clinical signs of autoimmune disease; our observation are in line with a previous 
work, in which patients affected by Sistemic Lupus Erythematosus were 
vaccinated, the safety of the influenza vaccination was demonstrated and no 
correlation with the worsening of the disease was found, although a  transient 
increase of ANA levels after vaccination was observed in some patients [276].  
To futher investigate the safety of influenza vaccination in our cKS patients, we 
also evaluated vaccination-induced HHV-8 virologic rebound in the serum. It is 
already demonstrated in HIV infected patients that vaccination leads to an increase 
il plasma virus [277, 278] but this has been shown to be a transient phenomenon 
and did not have any clinical significance [277]. We observed an increase of HHV-8 
DNA in 4 patients (8.7%), a lower frequency compared to HIV infected patients.  
Vaccination-induced HIV rebound was suggested to be a consequence of the 
activation of the immune system, which is a normal response to antigenic 
stimulation, and may enhance viral replication due to the critical role played by 
cellular activation in the initiation and propagation of HIV infection; also, Fauci 
proposed that inappropriate immune activation and elevated secretion of certain 
cytokines may compound the pathogenic process in HIV infected patients [279]. In 
our cKS patients immune activation from influenza vaccination may promote HHV-
8 rebound through the production of inflammatory cytokines, which have been 
suggested to play an important role in the initiation and progression of KS through 
reactivation of HHV-8 [280, 281]. It is important to note, however, that in no patient 
virologic rebound was associated with progression of KS lesions. 
Finally, we monitored whether a perturbation in the frequency of B cell 
subpopulations may occur after vaccination. We observed that cKS patients 
showed a higher frequency of immature/preimmune  B cells than healthy controls 
in all the time points, as previously determined, but we observed a slight decrease 
in the average of transitional B cells in cKS patients after vaccination. Transitional 
B cell decrease was observed in other infectious diseases such as parasitic 
disease; reduced lymphopoiesis and enhanced apoptosis were the events evoked 
to explain this observation [282]. We can hypothize that antigenic stimuli such as 
new infection or influenza vaccination can perturbe temporarily the frequency of 
transitional B cells through an excess production of pro-inflammatory citokines that 
negatively affects this lymphoid compartment [283]. Our study has some 
limitations: the last time point was 3 months after vaccination; anyway, the slight 
decrease in transitional B cell frequency was not associated with progression of the 
disease.  
To our knowledge, this is the first report concerning the effects of influenza 
vaccination on cKS patients and we demonstrated the safety and immunogenicity 
induced by influenza vaccination in cKS patients. This is relevant because annual 
influenza vaccination may be particularly recommended for cKS patients 
considering their advanced age and comorbidity. 
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5.1 Conclusion 
In conclusion in this study we report, for the first time to our knowledge, that HHV-8 
chronic infection promotes a perturbation of peripheral B cell homeostasis 
characterized by expansion of B cells of the preimmune/natural effector 
compartment, in patients with cKS without clinical signs of humoral immune 
deficiency. This novel observation may broaden our understanding of the complex 
interplay of viral and cellular factors leading HHV-8-infected individuals to develop 
either KS or lymphoproliferative malignancies. The discrepancy between the high 
number of HHV-8 infected subjects and the lower rate of subjects developing an 
HHV8- related disease suggests that immune control of the virus is lost in these 
subjects. It could be interesting to monitor a cohort of HHV-8-infected subjects that 
will and will not develop primary effusion lymphoma and the plasmablastic form of 
multicentric Castleman’s disease with the aim to broaden the comprehension of the 
mechanisms of viral tumorigenesis. Perspectively, long-term follow-up analysis of 
peripheral B cell changes in cKS patients will greatly help the comprehension of the 
mechanisms of viral tumorigenesis and possibly enable the development of 
efficient targeted therapies and novel treatment approaches. Moreover, the 
availability of a cell culture system an/or an animal model will extend the studies of 
KS pathogenesis and also the evaluation of antiviral agents and pathogenesis-
based therapies able to block viral products interfering with the cellular defense 
mechanisms such as cell cycle shutdown and apoptosis. 
Moreover, we demonstrated that influenza vaccination is safe and immunogenic on 
cKS patients compared to age- and sex-matched controls. It is well established that 
there is a complex regulatory network that actively inhibits immune responses 
during chronic viral infections such as HIV, HCV, or HBV infection so that we 
suggest that this study could be extended to evaluate the immune response to 
influenza vaccination in other subjects affected by chronic infection, to better 
determine similarities and differences of humoral response in chronic inflammation 
diseases. 
Generally, HHV-8 infection is considered harmless or unimportant but it plays a 
role in shaping the normal immune response and induce diseases in rare 
individuals. 
Future studies need to specifically focus on defining the mechanistic details of the 
disease and immunologic responses to viruses, so that we can intervene 
appropriately. 
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